0001564590-21-044162 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2021	Aug. 11, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Trading Symbol	VERO
Entity Registrant Name	Venus Concept Inc.
Entity Central Index Key	0001409269
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Security Exchange Name	NASDAQ
Entity File Number	001-38238
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	06-1681204
Entity Address, Address Line One	235 Yorkland Blvd.
Entity Address, Address Line Two	Suite 900
Entity Address, City or Town	Toronto
Entity Address, Postal Zip Code	M2J 4Y8
Entity Address, State or Province	ON
City Area Code	877
Local Phone Number	848-8430
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		54,146,435

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 23,059	$ 34,297
Restricted cash	83	83
Accounts receivable, net of allowance of $12,295 and $18,490 as of June 30, 2021, and December 31, 2020	50,078	52,764
Inventories	19,767	17,759
Prepaid expenses	2,350	2,240
Advances to suppliers	3,359	2,587
Other current assets	4,635	5,674
Total current assets	103,331	115,404
LONG-TERM ASSETS:
Long-term receivables	21,950	21,148
Deferred tax assets	1,196	884
Severance pay funds	715	685
Property and equipment, net	2,937	3,539
Intangible assets	17,144	18,865
Total long-term assets	43,942	45,121
TOTAL ASSETS	147,273	160,525
CURRENT LIABILITIES:
Trade payables	5,684	6,322
Accrued expenses and other current liabilities	17,096	20,253
Taxes payable	1,851	1,132
Unearned interest income	2,464	1,950
Warranty accrual	1,314	1,106
Deferred revenues	901	1,752
Current portion of government assistance loans	1,280
Total current liabilities	30,590	32,515
LONG-TERM LIABILITIES:
Long-term debt	76,396	75,491
Government assistance loans		4,110
Taxes payable	478	478
Accrued severance pay	819	755
Deferred tax liabilities	308	811
Unearned interest income	1,176	1,778
Warranty accrual	467	533
Other long-term liabilities	192	293
Total long-term liabilities	79,836	84,249
TOTAL LIABILITIES	110,426	116,764
Commitments and Contingencies (Note 8)
STOCKHOLDERS’ EQUITY (Note 1):
Common Stock, $0.0001 par value: 300,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 54,141,822 and 53,551,126 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	26	26
Additional paid-in capital (Note 1)	203,877	201,598
Accumulated deficit	(166,274)	(157,392)
TOTAL STOCKHOLDERS’ EQUITY	37,629	44,232
Non-controlling interests	(782)	(471)
Total equity	36,847	43,761
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 147,273	$ 160,525

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 12,295	$ 18,490
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	54,141,822	53,551,126
Common stock, shares outstanding	54,141,822	53,551,126

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue	$ 25,828	$ 16,996	$ 48,425	$ 31,504
Cost of goods sold	7,111	5,099	14,474	10,327
Gross profit	18,717	11,897	33,951	21,177
Operating expenses:
Selling and marketing	10,114	4,545	17,968	13,156
General and administrative	7,828	14,590	19,993	28,766
Research and development	2,024	1,570	4,075	4,194
Goodwill impairment				27,450
Gain on forgiveness of government assistance loans	(2,775)		(2,775)
Total operating expenses	17,191	20,705	39,261	73,566
Loss from operations	1,526	(8,808)	(5,310)	(52,389)
Other expenses:
Foreign exchange loss (gain)	130	(1,166)	844	3,113
Finance expenses	1,161	2,371	3,046	4,625
Loss on disposal of subsidiaries		385		385
Income (loss) before income taxes	235	(10,398)	(9,200)	(60,512)
Income tax benefit	(7)	(633)	(7)	(44)
Net income (loss)	242	(9,765)	(9,193)	(60,468)
Deemed dividend		(3,564)		(3,564)
Income (loss) attributable to stockholders of the Company	377	(13,152)	(8,882)	(63,342)
Loss attributable to non-controlling interest	$ (135)	$ (177)	$ (311)	$ (690)
Net income (loss) per share:
Basic	$ 0.01	$ (0.39)	$ (0.16)	$ (2.01)
Diluted	$ 0.01	$ (0.39)	$ (0.16)	$ (2.01)
Weighted-average number of shares used in per share calculation:
Basic	54,088	33,315	53,917	31,564
Diluted	54,237	33,315	53,917	31,564
Leases
Revenue	$ 12,787	$ 7,465	$ 21,324	$ 14,278
Cost of goods sold	2,736	1,541	4,506	2,993
Products and Services
Revenue	13,041	9,531	27,101	17,226
Cost of goods sold	$ 4,375	$ 3,558	$ 9,968	$ 7,334

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 242	$ (9,765)	$ (9,193)	$ (60,468)
Deemed dividend		3,564		3,564
Income (loss) attributable to stockholders of the Company	377	(13,152)	(8,882)	(63,342)
Loss attributable to non-controlling interest	(135)	(177)	(311)	(690)
Comprehensive income (loss)	$ 242	$ (9,765)	$ (9,193)	$ (60,468)

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Series A Preferred Shares	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Non-controlling Interest
Beginning balance, value at Dec. 31, 2019	$ 76,678		$ 24	$ 149,840	$ (75,686)	$ 2,500
Beginning balance, shares at Dec. 31, 2019			28,686,116
Issuance of common stock, shares			1,208,169
2020 Private Placement shares, net of costs	12,115			12,115
2020 Private Placement shares, net of costs, shares		660,000	2,300,000
2020 Private Placement Warrants, net of costs	4,621			4,621
Beneficial conversion feature	3,564			3,564
Dividends from subsidiaries	(218)					(218)
Net income (loss) - the Company	(50,190)				(50,190)
Net loss - non-controlling interest	(513)					(513)
Stock-based compensation	517			517
Ending balance, value at Mar. 31, 2020	46,574		$ 24	170,657	(125,876)	1,769
Ending balance, shares at Mar. 31, 2020		660,000	32,194,285
Beginning balance, value at Dec. 31, 2019	76,678		$ 24	149,840	(75,686)	2,500
Beginning balance, shares at Dec. 31, 2019			28,686,116
Net loss - non-controlling interest	(690)
Ending balance, value at Jun. 30, 2020	40,334		$ 25	174,622	(135,464)	1,151
Ending balance, shares at Jun. 30, 2020			39,830,122
Beginning balance, value at Mar. 31, 2020	46,574		$ 24	170,657	(125,876)	1,769
Beginning balance, shares at Mar. 31, 2020		660,000	32,194,285
Options exercised	34			34
Options exercised, shares			22,777
Issuance of common stock	3,393			3,393
Issuance of common stock, shares			1,013,060
Conversion of Preferred Stock Series A			$ 1	(1)
Conversion of Preferred Stock Series A, shares		(660,000)	6,600,000
Beneficial conversion feature	(3,564)			(3,564)
Deemed dividend	3,564			3,564
Disposal of subsidiary	(441)					(441)
Net income (loss) - the Company	(9,588)				(9,588)
Net loss - non-controlling interest	(177)					(177)
Stock-based compensation	539			539
Ending balance, value at Jun. 30, 2020	40,334		$ 25	174,622	(135,464)	1,151
Ending balance, shares at Jun. 30, 2020			39,830,122
Beginning balance, value at Dec. 31, 2020	43,761		$ 26	201,598	(157,392)	(471)
Beginning balance, shares at Dec. 31, 2020			53,551,126
December 2020 Public Offering warrants exercise	903			903
December 2020 Public Offering warrants exercise, shares			361,200
Options exercised	212			212
Options exercised, shares			157,304
Net income (loss) - the Company	(9,259)				(9,259)
Net loss - non-controlling interest	(176)					(176)
Stock-based compensation	508			508
Ending balance, value at Mar. 31, 2021	35,949		$ 26	203,221	(166,651)	(647)
Ending balance, shares at Mar. 31, 2021			54,069,630
Beginning balance, value at Dec. 31, 2020	$ 43,761		$ 26	201,598	(157,392)	(471)
Beginning balance, shares at Dec. 31, 2020			53,551,126
Options exercised, shares	229,496
Net loss - non-controlling interest	$ (311)
Ending balance, value at Jun. 30, 2021	36,847		$ 26	203,877	(166,274)	(782)
Ending balance, shares at Jun. 30, 2021			54,141,822
Beginning balance, value at Mar. 31, 2021	35,949		$ 26	203,221	(166,651)	(647)
Beginning balance, shares at Mar. 31, 2021			54,069,630
Options exercised	98			98
Options exercised, shares			72,192
Net income (loss) - the Company	377				377
Net loss - non-controlling interest	(135)					(135)
Stock-based compensation	558			558
Ending balance, value at Jun. 30, 2021	$ 36,847		$ 26	$ 203,877	$ (166,274)	$ (782)
Ending balance, shares at Jun. 30, 2021			54,141,822

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 242		$ (9,765)	$ (9,193)	$ (60,468)
Adjustments to reconcile net loss to net cash used in operating activities:
Goodwill impairment					27,450
Depreciation and amortization				2,451	2,514
Stock-based compensation				1,066	1,056
Provision for bad debt	(3,238)	$ 1,106		(2,132)	5,416	$ 15,212
Provision for inventory obsolescence				868	530
Finance expenses and accretion				849	4,134
Deferred tax recovery				(814)	(1,237)
Change in fair value of earn-out liability					244
Loss on sale of subsidiary					385
Loss on disposal of property and equipment					11
Gain on forgiveness of government assistance loans	(2,775)			(2,775)
Changes in operating assets and liabilities:
Accounts receivable short-term and long-term				4,028	6,187
Inventories				(2,877)	(986)
Prepaid expenses				(110)	88
Advances to suppliers				(772)
Other current assets				1,038	(2,483)
Other long-term assets				(12)	6
Trade payables				(640)	(385)
Accrued expenses and other current liabilities				(2,936)	(5,365)
Severance pay funds				(31)	72
Unearned interest income				(87)	(1,418)
Other long-term liabilities				(99)	(463)
Net cash used in operating activities				(12,178)	(24,712)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment				(126)	(108)
Cash received from sale of subsidiary, net of cash relinquished					89
Net cash used in investing activities				(126)	(19)
CASH FLOWS FROM FINANCING ACTIVITIES:
Exercises of 2020 December Public Offering Warrants				903
Payment of earn-out liability				(147)	(156)
Proceeds from exercise of options				310	34
Repayment of line-of-credit					(3,928)
Proceeds from government assistance loans					4,110
Proceeds from issuance of common stock					2,956
Proceeds from 2020 Private Placement, net of costs of $1,950					20,300
Dividends from subsidiaries paid to non-controlling interest					(218)
Net cash provided by financing activities				1,066	23,098
NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH				(11,238)	(1,633)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period		$ 34,380		34,380	15,749	15,749
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period	$ 23,142		$ 14,116	23,142	14,116	$ 34,380
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for income taxes				88	496
Cash paid for interest				$ 2,312	$ 173

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($)
Private Placement
Stock,issuance costs	$ 1,950

Nature of Operations

6 Months Ended

Jun. 30, 2021

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Nature of Operations

1. Nature of Operations

Venus Concept Inc. is a global medical technology company that develops, commercializes, and sells minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The Company’s systems have been designed on cost-effective, proprietary and flexible platforms that enable it to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family and general practitioners and aesthetic medical spas. The Company was incorporated in the state of Delaware on November 22, 2002. In these notes to the condensed consolidated financial statements, the “Company” and “Venus Concept”, refer to Venus Concept Inc. and its subsidiaries on a consolidated basis.

Going Concern

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business for the foreseeable future, and, as such, the unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

The Company has had recurring net operating losses and negative cash flows from operations. As of June 30, 2021 and December 31, 2020, the Company had an accumulated deficit of $166,274 and $157,392, respectively. The Company was in compliance with all required covenants as of June 30, 2021, and December 31, 2020. The Company’s recurring losses from operations and negative cash flows raise substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date that the unaudited condensed consolidated financial statements are issued. In addition, the coronavirus pandemic (“COVID-19” or “pandemic”) has had a significant negative impact on the Company’s results of operations as of June 30, 2021, and for the six months then ended, and management expects the pandemic to continue to have a negative impact in the foreseeable future, the extent of which is uncertain and largely subject to whether the severity of the pandemic worsens, or duration lengthens. In the event that the pandemic and the economic disruptions it has caused continue for an extended period of time, the Company cannot assure that it will remain in compliance with the financial covenants contained within its credit facilities.

In order to continue its operations, the Company must achieve profitable operations and/or obtain additional equity or debt financing. Until the Company achieves profitability, management plans to fund its operations and capital expenditures with cash on hand, borrowings, and issuance of capital stock. On December 22, 2020, the Company issued and sold to investors 11,250,000 shares of its common stock (“December 2020 Public Offering”), par value $0.0001 per share, at a combined offering price to the public of $2.00 per share and warrants (“December 2020 Public Offering Warrants”) to purchase up to 5,625,000 shares of common stock with an exercise price of $2.50 per share. The December 2020 Public Offering Warrants have a five-year term and are exercisable immediately. Total gross proceeds were $22,500. In February 2021, several investors exercised an aggregate of 361,200 December 2020 Public Offering Warrants at the exercise price of $2.50 per share. The total proceeds received by the Company from the December 2020 Public Offering Warrants exercises were $903. Until the Company generates revenue at a level to support its cost structure, the Company expects to continue to incur substantial operating losses and net cash outflows from operating activities.

Given the pandemic and the uncertainty around the COVID-19 variants, the Company cannot anticipate the extent to which the current economic turmoil and financial market conditions will continue to adversely impact the Company’s business and the Company may need additional capital to fund its future operations and to access the capital markets sooner than planned. There can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company. If the Company is unable to raise sufficient additional capital, it may be compelled to reduce the scope of its operations and planned capital expenditures or sell certain assets, including intellectual property assets. These unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from the uncertainty. Such adjustments could be material.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of Venus Concept Inc. have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2021. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K.

In the Form 10-Q for the period ended June 30, 2020, filed with the SEC on August 13, 2020, the loss on disposal of subsidiary in the amount of $385 as of June 30, 2020, was reported as a part of general and administrative expenses in the condensed consolidated statements of operations. The Company corrected the presentation and presented the loss on disposal of subsidiary as a separate item in the consolidated statements of operations in the Form 10-K for the year ended December 31, 2020, filed with the SEC on March 29, 2021, and in the accompanying unaudited condensed consolidated statements of operations.

The preparation of these unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2021 and through the date of this report filing. The accounting matters assessed included, but were not limited to, the allowance for doubtful accounts and the carrying value of intangible and long-lived assets.

Amounts reported in thousands within this report are computed based on the amounts in dollars. As a result, the sum of the components reported in thousands may not equal the total amount reported in thousands due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

Accounting Policies

The accounting policies the Company follows are set forth in the Company’s audited consolidated financial statements for fiscal year 2020. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K. There have been no material changes to these accounting policies.

JOBS Act Accounting Election

The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these unaudited condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.

Recently Issued Accounting Standards Not Yet Adopted

In April 2020, Financial Accounting Standards Board (the “FASB”) issued a Staff Question-and-Answer Document (Q&A): ASC Topic 842 and ASC Topic 840: Accounting for Lease Concessions Related to the Effects of the COVID-19 Pandemic, that focuses on the application of the lease guidance for lease concessions related solely to the effects of COVID-19. The FASB issued the guidelines to reduce the burden and complexity for companies to account for such lease concessions (e.g., rent abatements or other economic incentives) under current lease accounting rules due to COVID-19 by providing certain practical expedients that can be used. This guidance can be applied immediately. The Company anticipates that the adoption of the guidance will not have a material impact on the Company’s unaudited condensed consolidated financial statements.

In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04 - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASC Topic 848). This authoritative guidance provides optional relief for companies preparing for the discontinuation of interest rates such as LIBOR, which is expected to be phased out at the end of calendar 2021, and applies to lease contracts, hedging instruments, held-to-maturity debt securities and debt arrangements that have LIBOR as the benchmark rate. This guidance can be applied for a limited time, as of the beginning of the interim period that includes March 12, 2020 or any date thereafter, through December 31, 2022. The guidance may no longer be applied after December 31, 2022. In January 2021, the FASB issued authoritative guidance that makes amendments to the new rules on accounting for reference rate reform. The amendments clarify that all derivative instruments affected by the changes to interest rates used for discounting, margining or contract price alignment, regardless of whether they reference LIBOR, or another rate expected to be discontinued as a result of reference rate reform, an entity may apply certain practical expedients in ASC Topic 848. The Company is currently assessing the impact of applying this guidance as well as when to adopt this guidance.

In February 2020, the FASB issued authoritative guidance (ASU 2020-02 – Financial Instruments – Credit Losses (Topic 326) and Leases (Topic 842)) that amends and clarifies Topic 326 and Topic 842. For Topic 326, the codification was updated to include the SEC staff interpretations associated with registrants engaged in lending activities. ASC Topic 326 is effective for annual periods beginning after January 1, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of applying this guidance on its financial instruments, such as accounts receivable.

In December 2019, the FASB issued ASU 2019-12 – Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, an authoritative guidance that simplifies the accounting for income taxes by removing certain exceptions and making simplifications in other areas. It is effective from the first quarter of fiscal year 2022, with early adoption permitted in any interim period. If adopted early, the Company must adopt all the amendments in the same period. The amendments have differing adoption methods including retrospectively, prospectively and/or modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, depending on the specific change. The Company is currently evaluating the impact of applying this guidance and believes that it has transactions that may fall under the scope of this guidance.

Net Income (Loss) per Share

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Net Income (Loss) per Share

3. NET INCOME (LOSS) PER SHARE

Net Income (Loss) Per Share

Basic net income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common stock equivalents outstanding for the period determined using the treasury-stock method. For purposes of this calculation, common stock warrants and stock options are considered to be common stock equivalents and are only included in the calculation of diluted net income (loss) per share when their effect is dilutive.

The following table sets forth the computation of basic and diluted net income (loss) per share and the weighted average number of shares used in computing basic and diluted net income (loss) per share (in thousands, except per share data):

	Three Months Ended June 30					Six Months Ended June 30
	2021		2020			2021			2020
Numerator:
Net income (loss)	$	242	$	(9,765	)	$	(9,193	)	$	(60,468	)
Net income (loss) allocated to stockholders of the Company	$	377	$	(13,152	)	$	(8,882	)	$	(63,342	)
Denominator:
Weighted-average shares of common stock outstanding used in computing net income (loss) per share, basic		54,088		33,315			53,917			31,564
Weighted-average shares of common stock outstanding used in computing net income (loss) per share, diluted		54,237		33,315			53,917			31,564
Net income (loss) per share:
Basic	$	0.01	$	(0.39	)	$	(0.16	)	$	(2.01	)
Diluted	$	0.01	$	(0.39	)	$	(0.16	)	$	(2.01	)

Due to the net loss for the six months ended June 30, 2021, all the outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders because including them would have been antidilutive:

	June 30, 2021		June 30, 2020
Options to purchase common stock		5,794,087		4,787,295
Warrants for common stock		15,928,867		10,665,067
Total potential dilutive shares		21,722,954		15,452,362

Fair Value Measurements

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. FAIR VALUE MEASUREMENTS

Financial assets and financial liabilities are initially recognized at fair value when the Company becomes a party to the contractual provisions of the financial instrument. Subsequently, all financial instruments are measured at amortized cost using the effective interest method.

The financial instruments of the Company consist of cash and cash equivalents, restricted cash, accounts receivable, long-term receivables, lines of credit, trade payables, government assistance loans, accrued expenses and other current liabilities, earn-out liability, other long-term liabilities and long-term debt. In view of their nature, the fair value of these financial instruments approximates their carrying amounts.

The Company measures the fair value of its financial assets and liabilities using the fair value hierarchy. A financial instrument’s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1 - Quoted prices in active markets for identical assets or liabilities.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company classifies its restricted cash within Level 1. Guaranteed investment certificates are classified within Level 2 as the Company uses alternative pricing sources and models utilizing market observable inputs for valuation. Contingent earn-out consideration was classified within Level 3. The following tables set forth the fair value of the Company’s Level 1, Level 2 and Level 3 financial assets and liabilities within the fair value hierarchy:

	Fair Value Measurements as of June 30, 2021
	Quoted Prices in Active Markets using Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets
Guaranteed Investment Certificates (GIC)	$	—	$	66	$	—	$	66
Restricted cash		83		—		—		83
Total assets	$	83	$	66	$	—	$	149

	Fair Value Measurements as of December 31, 2020
	Quoted Prices in Active Markets using Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets
Guaranteed Investment Certificates (GIC)	$	—	$	64	$	—	$	64
Restricted cash		83		—		—		83
Total assets	$	83	$	64	$	—	$	147
Liabilities
Contingent earn-out consideration		—		—		147		147
Total liabilities	$	—	$	—	$	147	$	147

The earn-out liability was measured using discounted cash flow techniques, with the expected cash outflows estimated based on the assessed probability of the acquired business achieving the revenue metrics required for payment. Expected future revenues of the acquired business and the associated estimate of probability are not observable inputs. The payments due are based on point in time measurements of the metrics quarterly for two years from the acquisition date. Changes in the fair value of the earn-out liability were recognized in finance expenses in the unaudited condensed consolidated statements of operations.

The following table provides a roll forward of the aggregate fair values of the earn-out liability for the six months ended June 30, 2021, for which fair value is determined using Level 3 inputs:

Balance as of January 1, 2020	$	655
Payments		(799	)
Change in value		291
Balance as of December 31, 2020		147
Payments		(147	)
Change in value		-
Balance as of June 30, 2021	$	-

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accounts Receivable

6 Months Ended

Jun. 30, 2021

Receivables [Abstract]

Accounts Receivable

5. ACCOUNTS RECEIVABLE

The Company’s products may be sold under subscription agreements with title passing to the customer at the end of the lease term, which is generally 36 months. These arrangements are considered to be sales-type leases, where the present value of all cash flows to be received under the agreement is recognized upon shipment to the customer as lease revenue.

A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset on the Company's unaudited condensed consolidated balance sheets. The Company's financing receivables, consisting of sales-type leases, totaled $49,973 and $49,096 as of June 30, 2021 and December 31, 2020, respectively, and are included in accounts receivable and long-term receivables on the unaudited condensed consolidated balance sheets. The Company evaluates the credit quality of an obligor at lease inception and monitors credit quality over the term of the underlying transactions.

The Company performed an assessment of the allowance for doubtful accounts as of June 30, 2021 and December 31, 2020. Based upon such assessment, the Company recorded an allowance for doubtful accounts totaling $12,295 and $18,490 as of June 30, 2021, and December 31, 2020, respectively.

A summary of the Company’s accounts receivables is presented below:


	June 30, 2021			December 31, 2020
Gross accounts receivable	$	84,323		$	92,402
Unearned income		(3,640	)		(3,728	)
Allowance for doubtful accounts		(12,295	)		(18,490	)
	$	68,388		$	70,184
Reported as:
Current trade receivables	$	50,078		$	52,764
Current unearned interest income		(2,464	)		(1,950	)
Long-term trade receivables		21,950			21,148
Long-term unearned interest income		(1,176	)		(1,778	)
	$	68,388		$	70,184

Current subscription agreements are reported as part of accounts receivable. The following are the contractual commitments, net of allowance for doubtful accounts, to be received by the Company over the next 5 years:

			June 30,
	Total		2021		2022		2023		2024		2025
Current financing receivables, net of allowance of $4,683	$	28,024	$	28,024	$	—	$	—	$	—	$	—
Long-term financing receivables, net of allowance of $2,571		21,949		—		15,504		6,289		156		—
Total	$	49,973	$	28,024	$	15,504	$	6,289	$	156	$	—

Accounts receivable do not bear interest and are typically not collateralized. The Company performs ongoing credit evaluations of its customers’ financial condition and maintains an allowance for doubtful accounts. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts receivable are presented net of an allowance for doubtful accounts. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Actual losses may differ from our estimates and could be material to our consolidated financial position, results of operations and cash flows.

The allowance for doubtful accounts consisted of the following activity:

Balance as of January 1, 2020	$	10,494
Write-offs		(6,536	)
Provision		15,212
Sale of subsidiaries		(680	)
Balance as of December 31, 2020		18,490
Write-offs		(1,902	)
Provision		1,106
Balance as of March 31, 2021		17,694
Write-offs		(2,161	)
Recovery		(3,238	)
Balance as of June 30, 2021	$	12,295

Select Balance Sheet and Statement of Operations Information

6 Months Ended

Jun. 30, 2021

Select Balance Sheet And Income Statement Information [Abstract]

Select Balance Sheet and Statement of Operations Information

6. SELECT BALANCE SHEET AND STATEMENT OF OPERATIONS INFORMATION

Inventory

Inventory consists of the following:


	June 30, 2021		December 31, 2020
Raw materials	$	1,786	$	838
Work-in-progress		1,494		1,232
Finished goods		16,487		15,689
Total inventory	$	19,767	$	17,759

Additions to inventory are primarily comprised of newly produced units and applicators, refurbishment cost from demonstration units and used equipment which were reacquired during the three months from upgraded sales. The Company expensed $5,339 and $11,359 in cost of goods sold in the three and six months ended June 30, 2021 ($3,603 and $7,203 in the three and six months ended June 30, 2020). The balance of cost of goods sold represents the sale of applicators, parts and warranties.

The Company provides for excess and obsolete inventories when conditions indicate that the inventory cost is not recoverable due to physical deterioration, usage, obsolescence, reductions in estimated future demand and reductions in selling prices. Inventory provisions are measured as the difference between the cost of inventory and net realizable value to establish a lower cost basis for the inventories. As of June 30, 2021, a provision for obsolescence of $2,014 ($1,208 as of December 31, 2020) was taken against inventory.

Property and Equipment, Net

Property and equipment, net consist of the following:

	Useful Lives (in years)	June 30, 2021			December 31, 2020
Lab equipment tooling and molds	4 - 10	$	8,104		$	8,053
Office furniture and equipment	6 - 10		1,739			1,760
Leasehold improvements	up to 10		1,793			1,838
Computers and software	3		1,863			1,815
Vehicles	5 - 7		20			12
Total property and equipment			13,519			13,478
Less: Accumulated depreciation			(10,582	)		(9,939	)
Total property and equipment, net		$	2,937		$	3,539

Depreciation expense was $280 and $400 for the three months ended June 30, 2021 and 2020, respectively. Depreciation expense was $728 and $777 for the six months ended June 30, 2021 and 2020, respectively.

Other Current Assets

	June 30, 2021		December 31, 2020
Government remittances⁽¹⁾	$	1,436	$	1,009
Consideration receivable from sales of subsidiaries		2,199		2,580
Deferred financing costs		223		1,063
Sundry assets and miscellaneous		777		1,022
Total other current assets	$	4,635	$	5,674

(1)Government remittances are receivables from the local tax authorities for refunds of sales taxes and income taxes.

Accrued Expenses and Other Current Liabilities


	June 30, 2021		December 31, 2020
Payroll and related expense	$	1,442	$	1,312
Accrued expenses		6,387		8,582
Commission accrual		2,952		2,827
Sales and consumption taxes		6,315		7,532
Total accrued expenses and other current liabilities	$	17,096	$	20,253

Warranty Accrual

The following table provides the details of the change in the Company’s warranty accrual:

	June 30, 2021			December 31, 2020
Balance as of the beginning of the period	$	1,639		$	1,977
Warranties issued during the period		538			761
Warranty costs incurred during the period		(396	)		(1,099	)
Balance at the end of the period	$	1,781		$	1,639
Current		1,314			1,106
Long-term		467			533
Total	$	1,781		$	1,639

Finance Expenses

	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
Interest expense	$	930		2,220	$	2,068	$	4,328
Accretion on long-term debt and amortization of fees		231		151		978		297
Total finance expenses	$	1,161	$	2,371	$	3,046	$	4,625

Intangible Assets

6 Months Ended

Jun. 30, 2021

Goodwill And Intangible Assets Disclosure [Abstract]

Intangible Assets

7. INTANGIBLE ASSETS

Intangible assets net of accumulated amortization and goodwill were as follows:

	At June 30, 2021
	Gross Amount		Accumulated Amortization			Net Amount
Customer relationships	$	1,400	$	(288	)	$	1,112
Brand		2,500		(670	)		1,830
Technology		16,900		(4,683	)		12,217
Supplier agreement		3,000		(1,015	)		1,985
Total intangible assets	$	23,800	$	(6,656	)	$	17,144

	At December 31, 2020
	Gross Amount		Accumulated Amortization			Net Amount
Customer relationships	$	1,400	$	(242	)	$	1,158
Brand		2,500		(540	)		1,960
Technology		16,900		(3,286	)		13,614
Supplier agreement		3,000		(867	)		2,133
Total intangible assets	$	23,800	$	(4,935	)	$	18,865

Estimated amortization expense for the next five fiscal years and all years thereafter are as follows:


July 1, 2021 to December 31, 2021	$	1,752
2022		3,473
2023		3,473
2024		3,473
2025		3,004
Thereafter		1,969
Total	$	17,144

Commitments and Contingencies

6 Months Ended

Jun. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

8. COMMITMENTS AND CONTINGENCIES

Operating Leases

The Company has various operating lease agreements, which expire on various dates.

The Company recognizes rent expense on a straight-line basis over the non-cancellable lease period and records the difference between cash rent payments and the recognition of rent expense as a deferred rent liability. When leases contain escalation clauses, rent abatements and/or concessions, such as rent holidays and landlord or tenant incentives or allowances, the Company applies them in the determination of straight-line rent expense over the lease period.

Aggregate future minimum lease payments and purchase and service commitments with manufacturers and service providers as of June 30, 2021 are as follows:

	Office Lease		Purchase and Service Commitments		Total
July 1, 2021 to June 30, 2022	$	699	$	13,548	$	14,247
2023		739		—		739
2024		345		—		345
2025		213		—		213
2026		213		—		213
Thereafter		1,039		—		1,039
Total	$	3,248	$	13,548	$	16,796

The total rent expense for all operating leases for the three months ended June 30, 2021 and 2020 was $524 and $451, respectively. The total rent expense for all operating leases for the six months ended June 30, 2021 and 2020 was $1,095 and $1,021, respectively.

Commitments

As of June 30, 2021, the Company has non-cancellable purchase orders placed with its contract manufacturers in the amount of $12,760. In addition, as of June 30, 2021, the Company had $3,092 of open purchase orders that can be cancelled with 270 days’ notice, except for a portion equal to 15% of the total amount representing the purchase of “long lead items”.

On March 25, 2021, the Company entered into an endorsement agreement for the services of Venus Williams, four-time Olympic Gold Medalist, seven-time Grand Slam Champion and entrepreneur, pursuant to which Ms. Williams will act as a brand ambassador for Venus Bliss™.

Legal Proceedings

Purported Shareholder Class Actions

Between May 23, 2018 and June 11, 2019, four putative shareholder class action complaints were filed against Restoration Robotics, Inc., certain of its former officers and directors, certain of its venture capital investors, and the underwriters of the initial public offering (“IPO”). Two of these complaints, Wong v. Restoration Robotics, Inc., et al., No. 18CIV02609, and Li v. Restoration Robotics, Inc., et al., No. 19CIV08173 (together, the “State Actions”), were filed in the Superior Court of the State of California, County of San Mateo, and assert claims under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (the “Securities Act”). The other two complaints, Guerrini v. Restoration Robotics, Inc., et al., No. 5:18-cv-03712-EJD and Yzeiraj v. Restoration Robotics, Inc., et al., No. 5:18-cv-03883-BLF (together, the “Federal Actions”), were filed in the United States District Court for the Northern District of California and assert claims under Sections 11 and 15 of the Securities Act. The complaints all allege, among other things, that the Restoration Robotics’ Registration Statement filed with the SEC on September 1, 2017 and the Prospectus filed with the SEC on October 13, 2017 in connection with Restoration Robotics’ IPO were inaccurate and misleading, contained untrue statements of material facts, omitted to state other facts necessary to make the statements made not misleading and omitted to state material facts required to be stated therein. The complaints seek unspecified monetary damages, other equitable relief and attorneys’ fees and costs.

In the State Actions, Restoration Robotics, Inc., along with the other defendants, successfully demurred to the initial Wong complaint for failure to state a claim and secured a stay of both cases based on the forum selection clause contained in its Amended and Restated Certificate of Incorporation, which designates the federal district courts as the exclusive forums for claims arising under the Securities Act. However, on December 19, 2018, the Delaware Court of Chancery in Sciabacucchi v. Salzberg held that exclusive federal forum provisions are invalid under Delaware law. Based on this ruling, the San Mateo Superior Court lifted its stay of State Actions on December 10, 2019. On January 17, 2020, Plaintiffs in the State Actions filed a consolidated amended complaint for violations of federal securities laws, alleging again that, among other things, the Registration Statement filed with the SEC on September 1, 2017 and the Prospectus filed with the SEC on October 13, 2017 in connection with Restoration Robotics’ IPO were inaccurate and misleading, contained untrue statements of material facts, omitted to state other facts necessary to make the statements made not misleading and omitted to state material facts required to be stated therein. The complaint seeks unspecified monetary damages, other equitable relief and attorneys’ fees and costs. On February 24, 2020, the Company demurred to the consolidated amended complaint for failure to state a claim. On March 18, 2020, the Delaware Supreme Court reversed the Chancery Court’s decision in Sciabacucchi v. Salzberg and held that exclusive federal forum provisions are valid under Delaware law. On March 30, 2020, the Company filed a renewed motion to dismiss based on its federal forum selection clause. A hearing on the Company’s demurrer and renewed motion to dismiss was held on June 12, 2020. On September 1, 2020, the court granted the renewed motion to dismiss based on the Company’s forum selection clause as to the Company and individual defendants, but not as to the venture capital and underwriter defendants. On September 22, 2020, the Court entered a judgement of dismissal as to the Company and the individual defendants. On November 23, 2020, plaintiff filed a notice of appeal of the Court’s order granting the renewed motion to dismiss. On May 27, 2021, Plaintiff-Appellant Wong filed an opening brief in Wong v. Restoration Robotics, Inc., No. A161489 (Cal. Ct. App., 1st App. Dist., Div. 2). The Company’s responsive brief is due August 27, 2021. In the Federal Actions, which have been consolidated under the caption In re Restoration Robotics, Inc. Securities Litigation, Case No. 5:18-cv-03712-EJD, Lead Plaintiff Eduardo Guerrini (“Lead Plaintiff”) filed his consolidated amended complaint for violations of federal securities laws on November 30, 2018. The consolidated amended complaint alleges again that, among other things, Restoration Robotics’ Registration Statement filed with the SEC on September 1, 2017 and the Prospectus filed with the SEC on October 13, 2017 in connection with the IPO were inaccurate and misleading, contained untrue statements of material facts, omitted to state other facts necessary to make the statements made not misleading and omitted to state material facts required to be stated therein. On January 29, 2019, Restoration Robotics, Inc., along with certain of its former officers and directors, filed a motion to dismiss the consolidated amended complaint for failure to state a claim. On October 18, 2019, the District Court granted Restoration Robotics, Inc. motion to dismiss as to all but two allegedly false or misleading statements contained in the Company’s Prospectus. On December 9, 2019, the Company filed its answer to the consolidated amended complaint denying the falsity of these statements. On May 29, 2020, Lead Plaintiff filed a motion for class certification, which the Company elected not to oppose, and on July 29, 2020, the court certified a class of investors who purchased shares of the Company’s common stock pursuant or traceable to the Company’s IPO. On February 22, 2021, the District Court granted the parties’ joint stipulation to stay all pending deadlines on the basis that the parties had reached a settlement in principle for all claims in the Federal Actions. On July 29, 2021, Lead Plaintiff filed a motion for final approval of the settlement. A hearing on that motion is scheduled for September 2, 2021.

In addition to the State and Federal Actions, on July 11, 2019, a verified shareholder derivative complaint was filed in the United States District Court for the Northern District of California, captioned Mason v. Rhodes, No. 5:19-cv-03997-NC. The complaint alleges that certain of Restoration Robotics’ former officers and directors breached their fiduciary duties, have been unjustly enriched and violated Section 14(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) in connection with the IPO and Restoration Robotics’ 2018 proxy statement. The complaint seeks unspecified damages, declaratory relief, other equitable relief and attorneys’ fees and costs. On August 21, 2019, the District Court granted the parties’ joint stipulation to stay the Mason action during the pendency of the Federal Actions. On June 21, 2021, the District Court granted the parties’ further stipulation to stay the Mason action during the pendency of the Federal Action, and the case remains stayed.

Administrative Investigation Case

The Company’s Chinese subsidiary, Venus Concept China, imports and sells registered medical devices and unregistered non-medical devices in the People’s Republic of China (“PRC”). One of its unregistered products has been the subject of inquiries from two district level branches of the State Administration for Market Regulation, Xuhui MSA and Huangpu MSA, as to whether the product was properly sold as a non-medical device. In January 2019, Venus Concept China applied to register a version of this non-medical device as a medical device with the National Medical Products Administration of PRC (“NMPA”). On June 12, 2019, Venus Concept China was informed that Xuhui MSA had opened an administrative investigation case related to whether the device is an unregistered medical device, as a result of a complaint that Xuhui MSA received from a former distributor of Venus Concept China. Huangpu MSA notified Venus Concept China that it would be suspending its separate investigation against Venus Concept China, pending the results of the Xuhui MSA investigation. The Company and Venus Concept China have voluntarily stopped sales in China of this product.

On March 4, 2021, Xuhui MSA issued a written administrative penalty hearing notice (the “Notice”) to Venus Concept China. The Notice stated that Venus Concept China’s sale of Versa violated the relevant Chinese medical device administration regulation. As a result, Xuhui MSA proposed an administrative monetary penalty in the amount of approximately $150 or 976 Chinese Yuan (the “Penalty Amount”). On March 8, 2021, Venus Concept China gave written notice to Xuhui MSA that it accepted the penalty decision proposed by Xuhui MSA. On March 19, 2021, Xuhui MSA issued a written administrative penalty decision to Venus Concept China (the “Decision”), which affirmed the administrative penalty proposed by the Notice. On March 19, 2021, the same day the Decision was issued, Venus Concept China remitted the full Penalty Amount to Xuhui MSA. Acceptance of the payment of the Penalty Amount by Xuhui MSA resulted in the conclusion of its investigation case against Venus Concept China and settlement of this matter. This matter is now resolved and closed by Xuhui MSA.

Further, the Company may from time to time continue to be involved in various legal proceedings of a character normally incident to the ordinary course of its business, which the Company does not deem to be material to its business and results of operations.

Main Street Term Loan

6 Months Ended

Jun. 30, 2021

Main Street Term Loan

Debt Instrument [Line Items]

Main Street Term Loan/Madryn Long-term Debt and Convertible Notes

9. MAIN STREET TERM LOAN

On December 8, 2020, the Company executed a loan and security agreement (the “MSLP Loan Agreement”), a promissory note (the “MSLP Note”), and related documents for a loan in the aggregate amount of $50,000 for which City National Bank of Florida (“CNB”) will serve as a lender pursuant to the Main Street Priority Loan Facility as established by the Board of Governors of the Federal Reserve System Section 13(3) of the Federal Reserve Act (the “MSLP Loan”). On December 9, 2020, the MSLP Loan had been funded and the transaction was closed. The MSLP Note has a term of five years and bears interest at a rate per annum equal to 30-day LIBOR plus 3%. On December 8, 2023 and December 8, 2024, the Company must make an annual payment of principal plus accrued but unpaid interest in an amount equal to fifteen percent (15%) of the outstanding principal balance of the MSLP Note (inclusive of accrued but unpaid interest). The entire outstanding principal balance of the MSLP Note together with all accrued and unpaid interest is due and payable in full on December 8, 2025. The Company may prepay the MSLP Loan at any time without incurring any prepayment penalties. The MSLP Note provides for customary events of default, including, among others, those relating to a failure to make payment, bankruptcy, breaches of representations and covenants, and the occurrence of certain events. In addition, the MSLP Loan Agreement and MSLP Note contain various covenants that limit the Company’s ability to engage in specified types of transactions. Subject to limited exceptions, these covenants limit the Company’s ability, without CNB’s consent, to, among other things, sell, lease, transfer, exclusively license or dispose of our assets, incur, create or permit to exist additional indebtedness, or liens, to make dividends and other restricted payments, and to make certain changes to its ownership structure.

As of June 30, 2021 and December 31, 2020, the Company was in compliance with all required covenants.

The scheduled payments on the outstanding borrowings as of June 30, 2021 are as follows:

	As of June 30, 2021
2021	$	-
2022		1,599
2023		9,335
2024		7,938
2025		38,415
Total	$	57,287

Madryn Long-term Debt and Convertible Notes

6 Months Ended

Jun. 30, 2021

Madryn Long-term Debt and Convertible Notes

Debt Instrument [Line Items]

Main Street Term Loan/Madryn Long-term Debt and Convertible Notes

10. MADRYN LONG-TERM DEBT AND CONVERTIBLE NOTES

Madryn Exchange Agreement and Convertible Notes; Termination of Madryn Credit Agreement

On December 9, 2020, contemporaneously with the MSLP Loan Agreement (Note 9), the Company and its subsidiaries, Venus Concept USA, Inc. (“Venus USA”), Venus Concept Canada Corp. (“Venus Canada”), Venus Concept Ltd., and the Madryn Noteholders (as defined below), entered into a Securities Exchange Agreement (the “Exchange Agreement”) dated as of December 8, 2020, pursuant to which the Company (i) repaid $42,500 aggregate principal amount owed under that certain credit agreement originally entered into on October 11, 2016 and amended from time to time, between Venus Concept Ltd., Madryn Health Partners, LP and certain of its affiliates (the “Madryn Credit Agreement”), and (ii) issued, to the Madryn Health Partners (Cayman Master), LP and Madryn Health Partners, LP (together the “Madryn Noteholders”) secured subordinated convertible notes in the aggregate principal amount of $26,695 (the “Notes”). The Madryn Credit Agreement was terminated effective December 9, 2020 upon the funding and closing of the MSLP Loan and the issuance of the Notes.

The Notes will accrue interest at a rate of 8.0% per annum from the date of original issuance of the Notes to the third anniversary date of the original issuance and thereafter interest will accrue at a rate 6.0% per annum. Under certain circumstances, in the case of an event of default under the Notes, the then-applicable interest rate will increase by 4.0% per annum. Interest is payable quarterly in arrears on the last business day of each calendar quarter of each year after the original issuance date, beginning on December 31, 2020. The Notes will mature on December 9, 2025, unless earlier redeemed or converted. In connection with the Exchange Agreement, the Company also entered into, by and among the Company, Venus USA, Venus Canada, Venus Concept Ltd., and the Madryn Noteholders, (i) a Guaranty and Security Agreement dated as of December 9, 2020 (the “Madryn Security Agreement”), pursuant to which the Company agreed to grant Madryn a security interest in substantially all of its assets to secure the obligations under the Notes and (ii) a Subordination of Debt Agreement dated as of December 9, 2020 (the “CNB Subordination Agreement”). The security interests and liens granted to the Madryn Noteholders under the Madryn Security Agreement will terminate upon the earlier of (i) an assignment of the Notes (other than to an affiliate of the Madryn Noteholders) pursuant to the terms of the Exchange Agreement and (ii) the first date on which the outstanding principal amount of the Notes is less than $10,000. Obligations under the Notes are secured by substantially all of the assets of Venus Concept Inc. and its subsidiaries party to the Madryn Security Agreement. The Company’s obligations under the Notes and the security interests and liens created by the Madryn Security Agreement are subordinated to the Company’s indebtedness owing to CNB (including, but not limited, pursuant to the MSLP Loan Agreement and the CNB Loan Agreement, (Note 11)) and any security interests and liens which secure such indebtedness owing to CNB. The Notes are convertible at any time into shares of the Company’s common stock, par value $0.0001 per share, calculated by dividing the outstanding principal amount of the Notes (and any accrued and unpaid interest under the Notes) by the initial conversion price of $3.25 per share. In connection with the Notes, the Company recognized interest expense of $540 and $1,067 during the three and six months ended June 30, 2021. The conversion feature, providing the Madryn Noteholders with a right to receive the Company’s shares upon conversion of the Notes, was qualified for a scope exception in ASC 815-10-15 and did not require bifurcation. The Notes also contained embedded redemption features that provided multiple redemption alternatives. Certain redemption features provided the Madryn Noteholders with a right to receive cash and a variable number of shares upon change of control and an event of default (as defined in the Notes). The Company evaluated redemption upon change of control and an event of default under ASC 815, Derivatives and Hedging, and determined that these two redemption features required bifurcation. These embedded derivatives were accounted for as liabilities at their estimated fair value as of the date of issuance, and then subsequently remeasured to fair value as of each balance sheet date, with the related remeasurement adjustment being recognized as a component of change in fair value of derivative liabilities in the unaudited condensed consolidated statements of operations. The Company determined the likelihood of an event of default and change of control as remote as of June 30, 2021, and December 31, 2020, therefore a nominal value was allocated to the underlying embedded derivative liabilities as of June 30, 2021, and December 31, 2020.

The scheduled payments on the outstanding borrowings as of June 30, 2021 are as follows:

	As of June 30, 2021
2021	$	1,092
2022		2,165
2023		2,131
2024		1,628
2025		28,217
Total	$	35,233

For the three and six months ended June 30, 2021, the Company did not make any principal repayments.

Credit Facility

3 Months Ended

Mar. 31, 2021

Line Of Credit Facility [Abstract]

Credit Facility

11. Credit facility

The Company has an agreement with CNB pursuant to which CNB agreed to provide a revolving credit facility to the Company in the maximum principal amount of $10,000 to be used to finance working capital requirements (the “CNB Loan Agreement”).

The CNB Loan Agreement contains various covenants that limit the Company’s ability to engage in specified types of transactions. Subject to limited exceptions, these covenants limit the Company’s ability, without CNB’s consent, to, among other things, sell, lease, transfer, exclusively license or dispose of the Company’s assets, incur, create or permit to exist additional indebtedness, or liens, to make dividends and certain other restricted payments, and to make certain changes to its management and/or ownership structure. The CNB Loan Agreement also contains a covenant requiring that a minimum of $23,000 in cash be held in a deposit account maintained with CNB for one year following the closing of the CNB Loan Agreement, and after the first anniversary of the CNB Loan Agreement, a minimum of $3,000 in cash must be held in a deposit account maintained with CNB. The Madryn Noteholders have agreed to hold $20,000 in cash in an escrow account at CNB, and pursuant to an escrow agreement, such cash will be released back to the Madryn Noteholders on the first anniversary of the CNB Loan Agreement. The Company is required to maintain $3,000 in cash in a deposit account maintained with CNB at all times during the term of the CNB Loan Agreement. In addition, the CNB Loan Agreement contains certain covenants that require the Company to achieve certain minimum account balances, or a minimum debt service coverage ratio and a maximum total liability to tangible net worth ratio. If the Company fails to comply with these covenants, it will result in a default and require the Company to repay all outstanding principal amounts and any accrued interest. In connection with the CNB Loan Agreement, a loan fee of $1,000 was paid in equal installments on January 25, February 25 and March 25, 2021.

As of June 30, 2021, and December 31, 2020, the Company was in compliance with all required covenants. An event of default under this agreement would cause a default under the MSLP Loan (see Note 9).

The Company is currently in negotiations to renew the terms of the CNB Loan Agreement and anticipates this renewal to be completed in the third quarter of 2021.

Government Assistance Programs

6 Months Ended

Jun. 30, 2021

Government Assistance Programs [Abstract]

Government Assistance Programs

12. GOVERNMENT ASSISTANCE PROGRAMS

Venus Concept Inc. and Venus USA, received funding in the total amount of $4,048 in connection with two Small Business Loans under the federal Paycheck Protection Program provided in Section 7(a) of the Small Business Act of 1953, as amended by the Coronavirus Aid, Relief, and Economic Security Act, as amended from time to time (the “PPP”).

Venus Concept Inc. entered into a U.S. Small Business Administration Note dated as of April 21, 2020 in favor of CNB pursuant to which the Company borrowed $1,665 original principal amount, which was funded on April 29, 2020 (the “Venus Concept PPP Loan”). The Venus Concept PPP Loan bears interest at 1% per annum and matures in two years from the date of disbursement of funds under the loan. Interest and principal payments under the Venus Concept PPP Loan will be deferred for a period of six months.

The Venus Concept PPP Loan contains certain covenants which, among other things, restrict the Company’s use of the proceeds of the PPP Loan to the payment of payroll costs, interest on mortgage obligations, rent obligations and utility expenses, require compliance with all other loans or other agreements with any creditor of the Company, to the extent that a default under any loan or other agreement would materially affect the Company’s ability to repay its PPP Loan and limit the Company’s ability to make certain changes to its ownership structure.

Venus USA entered into a U.S. Small Business Administration Note dated as of April 15, 2020 in favor of CNB. Venus USA borrowed $2,383 original principal amount, which was funded on April 20, 2020 (the “Venus USA PPP Loan” and together with the Venus Concept PPP Loan, individually each a “PPP Loan” and collectively, the “PPP Loans”). The terms of the Venus USA PPP Loan are substantially similar to the terms of the Venus Concept PPP Loan.

Under certain circumstances, all or a portion of the PPP Loans may be forgiven. Through CNB, the Company applied for and received partial forgiveness of the Venus USA PPP Loan in the amount of $1,689 and the Venus Concept PPP Loan in the amount of $1,086. The remaining portion of the PPP Loans of the Company is recorded within the current liabilities in the unaudited condensed consolidated balance sheet.

Under the CNB Loan Agreement and the MSLP Loan Agreement, each PPP Loan is permitted to be incurred by Venus Concept Inc. and Venus USA as long as certain conditions remain satisfied. If Venus Concept Inc. and/or Venus USA defaults on the respective PPP Loan (i) events of default will occur under the CNB Loan Agreement and the MSLP Loan Agreement and (ii) Venus Concept Inc. and Venus USA may be required to immediately repay their respective PPP Loan.

As of June 30, 2021, the Company had $1,280 outstanding under the PPP Loans ($4,110 as of December 31, 2020).

In 2020, certain of the Company’s subsidiaries applied for government assistance programs and received government subsidies aggregating $1,117. The terms of these government assistance programs vary by jurisdiction. The Company recorded government subsidies received as a reduction to the associated wage costs in general and administrative expenses in the unaudited condensed consolidated statement of operations.

Common Stock Reserved For Issuance

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Common Stock Reserved For Issuance

13. COMMON STOCK RESERVED FOR ISSUANCE

The Company is required to reserve and keep available out of its authorized but unissued shares of common stock a number of shares sufficient to affect the exercise of all options granted and available for grant under the incentive plans and warrants to purchase common stock.

	June 30, 2021		December 31, 2020
Outstanding common stock warrants		15,928,867		16,290,067
Outstanding stock options		5,794,087		4,433,392
Shares reserved for future option grants		805,594		262,622
Shares reserved for Lincoln Park		5,222,867		5,222,867
Shares reserved for Madryn Noteholders		8,213,880		8,213,880
Total common stock reserved for issuance		35,965,295		34,422,828

Stockholders Equity

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Stockholders Equity

14. STOCKHOLDERS EQUITY

Common Stock

The Company’s common stock confers upon its holders the following rights:

•

The right to participate and vote in the Company’s stockholder meetings, whether annual or special. Each share will entitle its holder, when attending and participating in the voting in person or via proxy, to one vote;

•

The right to a share in the distribution of dividends, whether in cash or in the form of bonus shares, the distribution of assets or any other distribution pro rata to the par value of the shares held by them; and

•

The right to a share in the distribution of the Company’s excess assets upon liquidation pro rata to the par value of the shares held by them.

2020 Private Placement Warrants

In March 2020, the Company issued and sold to certain investors (collectively the “Investors”) warrants (the “2020 Private Placement Warrants”) to purchase up to 6,675,000 shares of common stock with an exercise price of $3.50 per share, along with the shares of common stock and preferred stock the Investors purchased (the “2020 Private Placement”). The 2020 Private Placement Warrants have a five-year term and are exercisable beginning 181 days after their issue date. The Company evaluated the 2020 Private Placement Warrants for liability or equity classification in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the warrants only require settlement through the issuance of the Company’s common stock, which is not redeemable, and do not represent an obligation to issue a variable number of shares. Based on this guidance, the Company determined, for each issuance, that the 2020 Private Placement Warrants did not need to be accounted for as a liability. Accordingly, the 2020 Private Placement Warrants were classified as equity and are not subject to remeasurement at each balance sheet date. The proceeds received in the 2020 Private Placement were allocated to each instrument on a relative fair value basis.

Total net proceeds of $20,300 reduced by $3,564 of the beneficial conversion feature were allocated as follows: $8,063 to Series A Preferred Stock, $4,052 to shares of common stock and $4,621 to the 2020 Private Placement Warrants issued. Series A Preferred Stock and common stock issued in the 2020 Private Placement were recorded at par value of $0.0001 with the excess of par value recorded in APIC. On June 16, 2020, upon the approval of the Company’s stockholders, 660,000 shares of Series A Preferred Stock were converted into 6,600,000 shares of the Company’s common stock.

December 2020 Public Offering Warrants and common stock

As noted in Note 1 above, in December 2020, the Company issued and sold to certain investors in the December 2020 Public Offering 11,250,000 shares of its common stock and warrants to purchase up to 5,625,000 shares of common stock with an exercise price of $2.50 per share. The December 2020 Public Offering Warrants have a five-year term and are exercisable immediately. The Company evaluated the December 2020 Public Offering Warrants for liability or equity classification in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, and determined that equity treatment was appropriate because the warrants only require settlement through the issuance of the Company’s common stock, which is not redeemable, and do not represent an obligation to issue a variable number of shares. Based on this guidance, the Company determined, for each issuance, that the December 2020 Public Offering Warrants did not need to be accounted for as a liability. Accordingly, the December 2020 Public Offering Warrants were classified as equity and are not subject to remeasurement at each balance sheet date. The proceeds received in the December 2020 Public Offering were allocated to each instrument on a relative fair value basis.

Total net proceeds of $20,476 were allocated as follows: $17,828 to shares of common stock and $2,648 to the December 2020 Public Offering Warrants issued. Common stock issued in the December 2020 Public Offering were recorded at par value of $0.0001 with the excess of par value recorded in APIC. In February 2021, several investors exercised an aggregate of 361,200 December 2020 Public Offering Warrants at the exercise price of $2.50 per share. The total proceeds received by the Company from the December 2020 Public Offering Warrants exercises were $903.

2010 Share Option Plan

In November 2010, the Company’s Board of Directors (the “Board”) adopted a share option plan (the “2010 Share Option Plan”) pursuant to which shares of the Company’s common stock are reserved for issuance upon the exercise of options to be granted to directors, officers, employees and consultants of the Company. The 2010 Share Option Plan is administered by the Board, which designates the options and dates of grant. Options granted vest over a period determined by the Board, originally had a contractual life of seven years, which was extended to ten years in November 2017 and are non-assignable except by the laws of descent. The Board has the authority to prescribe, amend and rescind rules and regulations relating to the 2010 Share Option Plan, provided that any such amendment or rescindment that would adversely affect the rights of an optionee that has received or been granted an option shall not be made without the optionee’s written consent. As of June 30, 2021, the number of shares of the Company’s common stock reserved for issuance and available for grant under the 2010 Share Option Plan was 180,208 (138,275 as of December 31, 2020).

2019 Incentive Award Plan

The 2019 Incentive Award Plan (the “2019 Plan”) was originally established under the name Restoration Robotics, Inc., as the 2017 Incentive Award Plan. It was adopted by the Board on September 12, 2017 and approved by the Company’s stockholders on September 14, 2017. The 2017 Incentive Award Plan was amended, restated, and renamed as set forth above, and was approved by the Company’s stockholders on October 4, 2019.

Under the 2019 Plan, 450,000 shares of common stock were initially reserved for issuance pursuant to a variety of stock-based compensation awards, including stock options, stock appreciation rights, performance stock awards, performance stock unit awards, restricted stock awards, restricted stock unit awards and other stock-based awards, plus the number of shares remaining available for future awards under the 2019 Plan as of the date we completed our business combination with Venus Concept Ltd. and the business of Venus Concept Ltd. became the primary business of the Company (the “Merger”). As of June 30, 2021, there were 625,386 shares of common stock available under the 2019 Plan (124,347 as of December 31, 2020). The 2019 Plan contains an “evergreen” provision, pursuant to which the number of shares of common stock reserved for issuance pursuant to awards under such plan shall be increased on the first day of each year from 2020 and ending in 2029 equal to the lesser of (A) four percent (4.00%) of the shares of stock outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares of stock as determined by the Board.

The Company recognized stock-based compensation for its employees and non-employees in the accompanying unaudited condensed consolidated statements of operations as follows:

	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
Cost of sales	$	8	$	6	$	15	$	12
Selling and marketing		224		222		441		414
General and administrative		297		284		561		583
Research and development		29		27		49		47
Total stock-based compensation	$	558	$	539	$	1,066	$	1,056

Stock Options

The fair value of each option is estimated at the date of grant using the Black-Scholes option pricing formula with the following assumptions:

	Three Months Ended June 30						Six Months Ended June 30
	2021			2020			2021			2020
Expected term (in years)		6.00			6.32			6.00		5.00-6.64
Risk-free interest rate	1.01-1.08		%		0.65	%	1.01-1.09		%	0.57-1.50		%
Expected volatility		44.00	%		43.26	%		44.75	%		42.61	%
Expected dividend rate		0	%		0	%		0	%		0	%

Expected Term—The expected term represents management’s best estimate for the options to be exercised by option holders.

Volatility—Since the Company does not have a trading history for its common stock, the expected volatility was derived from the historical stock volatilities of comparable peer public companies within its industry that are considered to be comparable to the Company’s business over a period equivalent to the expected term of the stock-based awards.

Risk-Free Interest Rate—The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant for zero-coupon U.S. Treasury notes with maturities approximately equal to the stock-based awards’ expected term.

Dividend Rate—The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its common stock in the foreseeable future.

Fair Value of Common Stock— Prior to the Merger, Venus Concept Ltd. used the price per share in its latest sale of securities as an estimate of the fair value of its ordinary shares. After the closing of the Merger, the fair value of the Company’s common stock is used to estimate the fair value of the stock-based awards at grant date.

The following table summarizes stock option activity under the Company’s stock option plans:

	Number of Shares			Weighted- Average Exercise Price per Share, $		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding – January 1, 2021		4,433,392		$	4.59		6.20	$	247
Options granted		1,984,500			2.34				1,520
Options exercised		(229,496	)		2.35				404
Options forfeited/cancelled		(394,309	)		4.68				25
Outstanding - June 30, 2021		5,794,087		$	3.94		7.31	$	2,279
Exercisable – June 30, 2021		2,593,882		$	4.70		5.00	$	823
Expected to vest – after June 30, 2021		3,200,205		$	3.34		9.18	$	1,456

The following tables summarize information about stock options outstanding and exercisable at June 30, 2021:

	Options Outstanding						Options Exercisable
Exercise Price Range	Number		Weighted average remaining contractual term (years)		Weighted average Exercise Price		Options exercisable		Weighted average remaining contractual term (years)		Weighted average Exercise Price
$1.35 - $3.64		4,391,390		7.60	$	2.80		1,587,140		4.53	$	2.92
$4.26 - $7.95		1,347,661		6.44		6.81		962,519		5.75		6.62
$12.45 - $26.10		33,659		6.75		18.48		23,033		6.57		18.82
$27.00 - $33.00		12,998		3.29		27.99		12,968		3.28		27.98
$36.00 - $94.65		8,379		6.19		45.42		8,222		6.18		45.17
		5,794,087		7.31	$	3.94		2,593,882		5.00	$	4.70

The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. The total intrinsic value of options exercised were $247 and $46 for the three months ended June 30, 2021 and 2020, respectively. The total intrinsic value of options exercised were $404 and $46 for the six months ended June 30, 2021 and 2020, respectively.

The weighted-average grant date fair value of options granted was $1.96 and $4.26 per share for the three months ended June 30, 2021 and 2020, respectively. The weighted-average grant date fair value of options granted was $2.34 and $4.355 per share for the six months ended June 30, 2021 and 2020, respectively.

Income Taxes

6 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Income Taxes

15. INCOME TAXES

The Company generated an income and recognized $7 of tax benefit for the three months ended June 30, 2021, and the Company generated a loss and recognized $633 of tax benefit for the three months ended June 30, 2020, respectively. The Company generated a loss and recognized $7 of tax benefit for the six months ended June 30, 2021 and $44 of tax benefit for the six months ended June 30, 2020, respectively. A reconciliation of income tax expense (benefit) is as follows:

	Three Months Ended June 30						Six Months Ended June 30
	2021			2020			2021			2020
Income (loss) before income taxes	$	235		$	(10,398	)	$	(9,200	)	$	(60,512	)
Theoretical tax expense (benefit) at the statutory rate (21.0% in 2021, 24.1% in 2020)		49			(2,507	)		(1,932	)		(14,584	)
Differences in jurisdictional tax rates		(49	)		(48	)		(403	)		(220	)
Losses recognition		—			101			—			—
Valuation allowance		315			1,936			2,299			7,298
Non-deductible expenses		(395	)		(115	)		(61	)		7,462
Other		73			—			90			—
Total income tax benefit		(7	)		(633	)		(7	)		(44	)
Net income (loss)	$	242		$	(9,765	)	$	(9,193	)	$	(60,468	)

Income tax benefit is recognized based on the actual income or loss incurred during the three months ended June 30, 2021 and 2020, respectively. Income tax benefit is recognized based on the actual income or loss incurred during the six months ended June 30, 2021 and 2020, respectively. Due to the uncertainties resulting from COVID-19, management was unable to determine an annualized effective tax rate and calculate the income tax expense in accordance with such method.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Segment and Geographic Information

6 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Segment and Geographic Information

16. SEGMENT AND GEOGRAPHIC INFORMATION

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company's CODM is its Chief Executive Officer. The Company has determined it operates in a single operating segment and has one reportable segment, as the CODM reviews financial information presented on a consolidated basis accompanied by disaggregated information about revenues by geography and type for purposes of making operating decisions, allocating resources, and evaluating financial performance. The Company does not assess the performance of individual product lines on measures of profit or loss, or asset-based metrics. Therefore, the information below is presented only for revenues by geography and type.

Revenue by geographic location, which is based on the product shipped to location, is summarized as follows:

	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
United States	$	13,186	$	8,915	$	24,063	$	14,555
International		12,642		8,081		24,362		16,949
Total revenue	$	25,828	$	16,996	$	48,425	$	31,504

As of June 30, 2021, long-lived assets in the amount of $17,906 were located in the United States and $2,175 were located in foreign locations. As of December 31, 2020, long-lived assets in the amount of $19,828 were located in the United States and $2,576 were located in foreign locations.

Revenue by type is a key indicator for providing management with an understanding of the Company’s financial performance, which is organized into four different categories:

1.Lease revenue - includes all system sales with typical lease terms of 36 months.

2.System revenue – includes all systems sales with payment terms within 12 months.

3.Product revenue – includes consumables payable upon receipt.

4.Service revenue - includes NeoGraft® technician services, advertising agency services and extended warranty sales.

The following table presents revenue by type:

	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
Lease revenue	$	12,787	$	7,465	$	21,324	$	14,278
System revenue		8,694		6,757		18,504		10,255
Product revenue		3,314		1,787		6,369		4,504
Service revenue		1,033		987		2,228		2,467
Total revenue	$	25,828	$	16,996	$	48,425	$	31,504

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Related Party Transactions

6 Months Ended

Jun. 30, 2021

Related Party Transactions

17. RELATED PARTY TRANSACTIONS

All amounts were recorded at the exchange amount, which is the amount established and agreed to by the related parties. The following are transactions between the Company and its related parties:

Distribution Agreements

On January 1, 2018, the Company entered into a distribution agreement with Technicalbiomed Co., Ltd. (“TBC”), pursuant to which TBC will continue to distribute the Company’s products in Thailand. A senior officer of the Company is a 30.0% shareholder of TBC. For the three months ended June 30, 2021 and 2020, TBC purchased products in the amount of $113 and $nil, respectively, under this distribution agreement. For the six months ended June 30, 2021 and 2020, TBC purchased products in the amount of $128 and $49, respectively, under this distribution agreement. These sales are included in products and services revenue.

In 2020, the Company made several strategic decisions to divest itself of underperforming direct sales offices and sold its share in several subsidiaries, including its 55.0% shareholding in Venus Concept Singapore Pte. Ltd (“Venus Singapore”). On January 1, 2021, the Company entered into a distribution agreement with Venus Singapore, pursuant to which Venus Singapore will continue to distribute the Company’s products in Singapore. A senior officer of the Company is a 45.0% shareholder of Venus Singapore. For the three and six months ended June 30, 2021, Venus Singapore purchased products in the amount of $49 and $114, respectively, under the distribution agreement. These sales are included in products and services revenue.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Venus Concept Inc. have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission (the “SEC”) on March 29, 2021. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the six months ended June 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K. In the Form 10-Q for the period ended June 30, 2020, filed with the SEC on August 13, 2020, the loss on disposal of subsidiary in the amount of $385 as of June 30, 2020, was reported as a part of general and administrative expenses in the condensed consolidated statements of operations. The Company corrected the presentation and presented the loss on disposal of subsidiary as a separate item in the consolidated statements of operations in the Form 10-K for the year ended December 31, 2020, filed with the SEC on March 29, 2021, and in the accompanying unaudited condensed consolidated statements of operations. The preparation of these unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ materially from those estimates. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2021 and through the date of this report filing. The accounting matters assessed included, but were not limited to, the allowance for doubtful accounts and the carrying value of intangible and long-lived assets. Amounts reported in thousands within this report are computed based on the amounts in dollars. As a result, the sum of the components reported in thousands may not equal the total amount reported in thousands due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars. Accounting Policies The accounting policies the Company follows are set forth in the Company’s audited consolidated financial statements for fiscal year 2020. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of the Company’s most recent Annual Report on Form 10-K. There have been no material changes to these accounting policies.
Jobs Act Accounting Election	JOBS Act Accounting Election The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i) no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, these unaudited condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
Recently Issued Accounting Standards Not Yet Adopted	Recently Issued Accounting Standards Not Yet Adopted In April 2020, Financial Accounting Standards Board (the “FASB”) issued a Staff Question-and-Answer Document (Q&A): ASC Topic 842 and ASC Topic 840: Accounting for Lease Concessions Related to the Effects of the COVID-19 Pandemic, that focuses on the application of the lease guidance for lease concessions related solely to the effects of COVID-19. The FASB issued the guidelines to reduce the burden and complexity for companies to account for such lease concessions (e.g., rent abatements or other economic incentives) under current lease accounting rules due to COVID-19 by providing certain practical expedients that can be used. This guidance can be applied immediately. The Company anticipates that the adoption of the guidance will not have a material impact on the Company’s unaudited condensed consolidated financial statements. In March 2020, the FASB issued Accounting Standards Update (“ASU”) 2020-04 - Facilitation of the Effects of Reference Rate Reform on Financial Reporting (ASC Topic 848). This authoritative guidance provides optional relief for companies preparing for the discontinuation of interest rates such as LIBOR, which is expected to be phased out at the end of calendar 2021, and applies to lease contracts, hedging instruments, held-to-maturity debt securities and debt arrangements that have LIBOR as the benchmark rate. This guidance can be applied for a limited time, as of the beginning of the interim period that includes March 12, 2020 or any date thereafter, through December 31, 2022. The guidance may no longer be applied after December 31, 2022. In January 2021, the FASB issued authoritative guidance that makes amendments to the new rules on accounting for reference rate reform. The amendments clarify that all derivative instruments affected by the changes to interest rates used for discounting, margining or contract price alignment, regardless of whether they reference LIBOR, or another rate expected to be discontinued as a result of reference rate reform, an entity may apply certain practical expedients in ASC Topic 848. The Company is currently assessing the impact of applying this guidance as well as when to adopt this guidance. In February 2020, the FASB issued authoritative guidance (ASU 2020-02 – Financial Instruments – Credit Losses (Topic 326) and Leases (Topic 842)) that amends and clarifies Topic 326 and Topic 842. For Topic 326, the codification was updated to include the SEC staff interpretations associated with registrants engaged in lending activities. ASC Topic 326 is effective for annual periods beginning after January 1, 2023, including interim periods within those fiscal years. The Company is currently evaluating the impact of applying this guidance on its financial instruments, such as accounts receivable. In December 2019, the FASB issued ASU 2019-12 – Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, an authoritative guidance that simplifies the accounting for income taxes by removing certain exceptions and making simplifications in other areas. It is effective from the first quarter of fiscal year 2022, with early adoption permitted in any interim period. If adopted early, the Company must adopt all the amendments in the same period. The amendments have differing adoption methods including retrospectively, prospectively and/or modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption, depending on the specific change. The Company is currently evaluating the impact of applying this guidance and believes that it has transactions that may fall under the scope of this guidance.

Net Income (Loss) per Share (Tables)

6 Months Ended

Jun. 30, 2021

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Income (Loss) Per Share and Weighted Average Number of Shares Used in Computing Basic and Diluted Net Income (Loss) Per Share

	Three Months Ended June 30					Six Months Ended June 30
	2021		2020			2021			2020
Numerator:
Net income (loss)	$	242	$	(9,765	)	$	(9,193	)	$	(60,468	)
Net income (loss) allocated to stockholders of the Company	$	377	$	(13,152	)	$	(8,882	)	$	(63,342	)
Denominator:
Weighted-average shares of common stock outstanding used in computing net income (loss) per share, basic		54,088		33,315			53,917			31,564
Weighted-average shares of common stock outstanding used in computing net income (loss) per share, diluted		54,237		33,315			53,917			31,564
Net income (loss) per share:
Basic	$	0.01	$	(0.39	)	$	(0.16	)	$	(2.01	)
Diluted	$	0.01	$	(0.39	)	$	(0.16	)	$	(2.01	)

Outstanding Shares of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders

	June 30, 2021		June 30, 2020
Options to purchase common stock		5,794,087		4,787,295
Warrants for common stock		15,928,867		10,665,067
Total potential dilutive shares		21,722,954		15,452,362

Fair Value Measurements - (Tables)

6 Months Ended

Jun. 30, 2021

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Level 1, Level 2 and Level 3 Financial Assets and Liabilities

The following tables set forth the fair value of the Company’s Level 1, Level 2 and Level 3 financial assets and liabilities within the fair value hierarchy:

	Fair Value Measurements as of June 30, 2021
	Quoted Prices in Active Markets using Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets
Guaranteed Investment Certificates (GIC)	$	—	$	66	$	—	$	66
Restricted cash		83		—		—		83
Total assets	$	83	$	66	$	—	$	149

	Fair Value Measurements as of December 31, 2020
	Quoted Prices in Active Markets using Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets
Guaranteed Investment Certificates (GIC)	$	—	$	64	$	—	$	64
Restricted cash		83		—		—		83
Total assets	$	83	$	64	$	—	$	147
Liabilities
Contingent earn-out consideration		—		—		147		147
Total liabilities	$	—	$	—	$	147	$	147

Schedule Aggregate Fair Values of Earn-out Liability

The following table provides a roll forward of the aggregate fair values of the earn-out liability for the six months ended June 30, 2021, for which fair value is determined using Level 3 inputs:

Balance as of January 1, 2020	$	655
Payments		(799	)
Change in value		291
Balance as of December 31, 2020		147
Payments		(147	)
Change in value		-
Balance as of June 30, 2021	$	-

Accounts Receivable (Tables)

6 Months Ended

Jun. 30, 2021

Receivables [Abstract]

Summary of Accounts Receivables

A summary of the Company’s accounts receivables is presented below:


	June 30, 2021			December 31, 2020
Gross accounts receivable	$	84,323		$	92,402
Unearned income		(3,640	)		(3,728	)
Allowance for doubtful accounts		(12,295	)		(18,490	)
	$	68,388		$	70,184
Reported as:
Current trade receivables	$	50,078		$	52,764
Current unearned interest income		(2,464	)		(1,950	)
Long-term trade receivables		21,950			21,148
Long-term unearned interest income		(1,176	)		(1,778	)
	$	68,388		$	70,184

Schedule of Contractual Commitments, Net of Allowance for Doubtful Accounts

The following are the contractual commitments, net of allowance for doubtful accounts, to be received by the Company over the next 5 years:

			June 30,
	Total		2021		2022		2023		2024		2025
Current financing receivables, net of allowance of $4,683	$	28,024	$	28,024	$	—	$	—	$	—	$	—
Long-term financing receivables, net of allowance of $2,571		21,949		—		15,504		6,289		156		—
Total	$	49,973	$	28,024	$	15,504	$	6,289	$	156	$	—

Summary of Allowance for Doubtful Accounts

The allowance for doubtful accounts consisted of the following activity:

Balance as of January 1, 2020	$	10,494
Write-offs		(6,536	)
Provision		15,212
Sale of subsidiaries		(680	)
Balance as of December 31, 2020		18,490
Write-offs		(1,902	)
Provision		1,106
Balance as of March 31, 2021		17,694
Write-offs		(2,161	)
Recovery		(3,238	)
Balance as of June 30, 2021	$	12,295

Select Balance Sheet and Statement of Operations Information (Tables)

6 Months Ended

Jun. 30, 2021

Select Balance Sheet And Income Statement Information [Abstract]

Schedule of Inventory

Inventory consists of the following:


	June 30, 2021		December 31, 2020
Raw materials	$	1,786	$	838
Work-in-progress		1,494		1,232
Finished goods		16,487		15,689
Total inventory	$	19,767	$	17,759

Schedule of Property and Equipment, Net

Property and equipment, net consist of the following:

	Useful Lives (in years)	June 30, 2021			December 31, 2020
Lab equipment tooling and molds	4 - 10	$	8,104		$	8,053
Office furniture and equipment	6 - 10		1,739			1,760
Leasehold improvements	up to 10		1,793			1,838
Computers and software	3		1,863			1,815
Vehicles	5 - 7		20			12
Total property and equipment			13,519			13,478
Less: Accumulated depreciation			(10,582	)		(9,939	)
Total property and equipment, net		$	2,937		$	3,539

Schedule of Other Current Assets

Other Current Assets

	June 30, 2021		December 31, 2020
Government remittances⁽¹⁾	$	1,436	$	1,009
Consideration receivable from sales of subsidiaries		2,199		2,580
Deferred financing costs		223		1,063
Sundry assets and miscellaneous		777		1,022
Total other current assets	$	4,635	$	5,674

(1)Government remittances are receivables from the local tax authorities for refunds of sales taxes and income taxes.

Schedule of Accrued Expenses and Other Current Liabilities


	June 30, 2021		December 31, 2020
Payroll and related expense	$	1,442	$	1,312
Accrued expenses		6,387		8,582
Commission accrual		2,952		2,827
Sales and consumption taxes		6,315		7,532
Total accrued expenses and other current liabilities	$	17,096	$	20,253

Schedule of Change in Warranty Accrual

The following table provides the details of the change in the Company’s warranty accrual:

	June 30, 2021			December 31, 2020
Balance as of the beginning of the period	$	1,639		$	1,977
Warranties issued during the period		538			761
Warranty costs incurred during the period		(396	)		(1,099	)
Balance at the end of the period	$	1,781		$	1,639
Current		1,314			1,106
Long-term		467			533
Total	$	1,781		$	1,639

Schedule of Finance Expenses

	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
Interest expense	$	930		2,220	$	2,068	$	4,328
Accretion on long-term debt and amortization of fees		231		151		978		297
Total finance expenses	$	1,161	$	2,371	$	3,046	$	4,625

Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2021

Goodwill And Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets Net of Accumulated Amortization and Goodwill

Intangible assets net of accumulated amortization and goodwill were as follows:

	At June 30, 2021
	Gross Amount		Accumulated Amortization			Net Amount
Customer relationships	$	1,400	$	(288	)	$	1,112
Brand		2,500		(670	)		1,830
Technology		16,900		(4,683	)		12,217
Supplier agreement		3,000		(1,015	)		1,985
Total intangible assets	$	23,800	$	(6,656	)	$	17,144

	At December 31, 2020
	Gross Amount		Accumulated Amortization			Net Amount
Customer relationships	$	1,400	$	(242	)	$	1,158
Brand		2,500		(540	)		1,960
Technology		16,900		(3,286	)		13,614
Supplier agreement		3,000		(867	)		2,133
Total intangible assets	$	23,800	$	(4,935	)	$	18,865

Schedule of Estimated Amortization Expense

Estimated amortization expense for the next five fiscal years and all years thereafter are as follows:


July 1, 2021 to December 31, 2021	$	1,752
2022		3,473
2023		3,473
2024		3,473
2025		3,004
Thereafter		1,969
Total	$	17,144

Commitments and Contingencies (Tables)

6 Months Ended

Jun. 30, 2021

Commitments And Contingencies Disclosure [Abstract]

Summary of Future Minimum Lease Payments and Purchase and Service Commitments with Manufacturers and Service Providers

Aggregate future minimum lease payments and purchase and service commitments with manufacturers and service providers as of June 30, 2021 are as follows:

	Office Lease		Purchase and Service Commitments		Total
July 1, 2021 to June 30, 2022	$	699	$	13,548	$	14,247
2023		739		—		739
2024		345		—		345
2025		213		—		213
2026		213		—		213
Thereafter		1,039		—		1,039
Total	$	3,248	$	13,548	$	16,796

Main Street Term Loan (Tables)

6 Months Ended

Jun. 30, 2021

Debt Instrument [Line Items]

Schedule Payments on Outstanding Borrowings

The scheduled payments on the outstanding borrowings as of June 30, 2021 are as follows:

	As of June 30, 2021
2021	$	1,092
2022		2,165
2023		2,131
2024		1,628
2025		28,217
Total	$	35,233

MSLP Loan Agreement

Debt Instrument [Line Items]

Schedule Payments on Outstanding Borrowings

The scheduled payments on the outstanding borrowings as of June 30, 2021 are as follows:

	As of June 30, 2021
2021	$	-
2022		1,599
2023		9,335
2024		7,938
2025		38,415
Total	$	57,287

Madryn Long-term Debt and Convertible Notes (Tables)

6 Months Ended

Jun. 30, 2021

Debt Disclosure [Abstract]

Schedule Payments on Outstanding Borrowings

The scheduled payments on the outstanding borrowings as of June 30, 2021 are as follows:

	As of June 30, 2021
2021	$	1,092
2022		2,165
2023		2,131
2024		1,628
2025		28,217
Total	$	35,233

Common Stock Reserved For Issuance (Tables)

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Schedule of Common Stock Reserved for Issuance

	June 30, 2021		December 31, 2020
Outstanding common stock warrants		15,928,867		16,290,067
Outstanding stock options		5,794,087		4,433,392
Shares reserved for future option grants		805,594		262,622
Shares reserved for Lincoln Park		5,222,867		5,222,867
Shares reserved for Madryn Noteholders		8,213,880		8,213,880
Total common stock reserved for issuance		35,965,295		34,422,828

Stockholders Equity (Tables)

6 Months Ended

Jun. 30, 2021

Equity [Abstract]

Summary of Recognized Stock-based Compensation Expense for Employees and Non-employees

The Company recognized stock-based compensation for its employees and non-employees in the accompanying unaudited condensed consolidated statements of operations as follows:

	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
Cost of sales	$	8	$	6	$	15	$	12
Selling and marketing		224		222		441		414
General and administrative		297		284		561		583
Research and development		29		27		49		47
Total stock-based compensation	$	558	$	539	$	1,066	$	1,056

Assumptions used in Fair Value of Option Estimated at Date of Grant using Black-Scholes-Merton Option Pricing Formula

The fair value of each option is estimated at the date of grant using the Black-Scholes option pricing formula with the following assumptions:

	Three Months Ended June 30						Six Months Ended June 30
	2021			2020			2021			2020
Expected term (in years)		6.00			6.32			6.00		5.00-6.64
Risk-free interest rate	1.01-1.08		%		0.65	%	1.01-1.09		%	0.57-1.50		%
Expected volatility		44.00	%		43.26	%		44.75	%		42.61	%
Expected dividend rate		0	%		0	%		0	%		0	%

Summary of Stock Option Activity

The following table summarizes stock option activity under the Company’s stock option plans:

	Number of Shares			Weighted- Average Exercise Price per Share, $		Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding – January 1, 2021		4,433,392		$	4.59		6.20	$	247
Options granted		1,984,500			2.34				1,520
Options exercised		(229,496	)		2.35				404
Options forfeited/cancelled		(394,309	)		4.68				25
Outstanding - June 30, 2021		5,794,087		$	3.94		7.31	$	2,279
Exercisable – June 30, 2021		2,593,882		$	4.70		5.00	$	823
Expected to vest – after June 30, 2021		3,200,205		$	3.34		9.18	$	1,456

Summary of Information about Stock Options Outstanding and Exercisable

The following tables summarize information about stock options outstanding and exercisable at June 30, 2021:

	Options Outstanding						Options Exercisable
Exercise Price Range	Number		Weighted average remaining contractual term (years)		Weighted average Exercise Price		Options exercisable		Weighted average remaining contractual term (years)		Weighted average Exercise Price
$1.35 - $3.64		4,391,390		7.60	$	2.80		1,587,140		4.53	$	2.92
$4.26 - $7.95		1,347,661		6.44		6.81		962,519		5.75		6.62
$12.45 - $26.10		33,659		6.75		18.48		23,033		6.57		18.82
$27.00 - $33.00		12,998		3.29		27.99		12,968		3.28		27.98
$36.00 - $94.65		8,379		6.19		45.42		8,222		6.18		45.17
		5,794,087		7.31	$	3.94		2,593,882		5.00	$	4.70

Income Taxes (Tables)

6 Months Ended

Jun. 30, 2021

Income Tax Disclosure [Abstract]

Schedule of Reconciliation of Income Tax Expense

	Three Months Ended June 30						Six Months Ended June 30
	2021			2020			2021			2020
Income (loss) before income taxes	$	235		$	(10,398	)	$	(9,200	)	$	(60,512	)
Theoretical tax expense (benefit) at the statutory rate (21.0% in 2021, 24.1% in 2020)		49			(2,507	)		(1,932	)		(14,584	)
Differences in jurisdictional tax rates		(49	)		(48	)		(403	)		(220	)
Losses recognition		—			101			—			—
Valuation allowance		315			1,936			2,299			7,298
Non-deductible expenses		(395	)		(115	)		(61	)		7,462
Other		73			—			90			—
Total income tax benefit		(7	)		(633	)		(7	)		(44	)
Net income (loss)	$	242		$	(9,765	)	$	(9,193	)	$	(60,468	)

Segment and Geographic Information (Tables)

6 Months Ended

Jun. 30, 2021

Segment Reporting [Abstract]

Schedule of Revenue by Geographic Area

Revenue by geographic location, which is based on the product shipped to location, is summarized as follows:

	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
United States	$	13,186	$	8,915	$	24,063	$	14,555
International		12,642		8,081		24,362		16,949
Total revenue	$	25,828	$	16,996	$	48,425	$	31,504

Schedule of Revenue by Type

The following table presents revenue by type:

	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
Lease revenue	$	12,787	$	7,465	$	21,324	$	14,278
System revenue		8,694		6,757		18,504		10,255
Product revenue		3,314		1,787		6,369		4,504
Service revenue		1,033		987		2,228		2,467
Total revenue	$	25,828	$	16,996	$	48,425	$	31,504

Nature of Operations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	6 Months Ended
	Dec. 22, 2020	Feb. 28, 2021	Jun. 30, 2021	Dec. 31, 2020
Nature Of Operations [Line Items]
Accumulated deficit			$ 166,274	$ 157,392
Common stock, par value			$ 0.0001	$ 0.0001
Exercises of 2020 December Public Offering Warrants			$ 903
December 2020 Public Offering
Nature Of Operations [Line Items]
Common stock, shares issued	11,250,000
Combined offering price per share	$ 2.00
December 2020 Public Offering \| Common Stock
Nature Of Operations [Line Items]
Common stock, par value	0.0001
December 2020 Public Offering Warrants
Nature Of Operations [Line Items]
Warrants to purchase shares of common stock		361,200
Exercise price of warrants	$ 2.50	$ 2.50
Warrants expiry period	5 years
Warrants exercisable period			The December 2020 Public Offering Warrants have a five-year term and are exercisable immediately.
Gross proceeds from stock issuance	$ 22,500
Exercises of 2020 December Public Offering Warrants		$ 903
Maximum \| December 2020 Public Offering Warrants
Nature Of Operations [Line Items]
Warrants to purchase shares of common stock	5,625,000

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Accounting Policies [Abstract]
Loss on disposal of subsidiaries	$ 385	$ 385

Net Income (Loss) per Share - Computation of Basic and Diluted Net Income (Loss) Per Share and Weighted Average Number of Shares Used in Computing Basic and Diluted Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net income (loss)	$ 242	$ (9,765)	$ (9,193)	$ (60,468)
Net income (loss) allocated to stockholders of the Company	$ 377	$ (13,152)	$ (8,882)	$ (63,342)
Denominator:
Weighted-average shares of common stock outstanding used in computing net income (loss) per share, basic	54,088	33,315	53,917	31,564
Weighted-average shares of common stock outstanding used in computing net income (loss) per share, diluted	54,237	33,315	53,917	31,564
Net income (loss) per share:
Basic	$ 0.01	$ (0.39)	$ (0.16)	$ (2.01)
Diluted	$ 0.01	$ (0.39)	$ (0.16)	$ (2.01)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

+ Details

Net Income (Loss) per Share - Outstanding Shares of Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	21,722,954	15,452,362
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	5,794,087	4,787,295
Warrants for Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	15,928,867	10,665,067

Fair Value Measurements - Schedule of Fair Value of Level 1, Level 2 and Level 3 Financial Assets and Liabilities - (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	$ 149	$ 147
Total liabilities		147
Quoted Prices in Active Markets using Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	83	83
Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	66	64
Significant Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total liabilities		147
Guaranteed Investment Certificates
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	66	64
Guaranteed Investment Certificates \| Significant Other Observable Inputs (Level 2)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	66	64
Restricted Cash
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	83	83
Restricted Cash \| Quoted Prices in Active Markets using Identical Assets (Level 1)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total assets	$ 83	83
Contingent Earn-out Consideration
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total liabilities		147
Contingent Earn-out Consideration \| Significant Unobservable Inputs (Level 3)
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total liabilities		$ 147

Fair Value Measurements - Schedule Aggregate Fair Values of Earn-out Liability - (Details) - Level 3 - Contingent Earn-out Consideration - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 147	$ 655
Payments	$ (147)	(799)
Change in value		291
Ending balance		$ 147

Accounts Receivable - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Notes and Loans Receivable [Line Items]
Sales-type leases term of lease	36 months
Allowance for doubtful accounts	$ 12,295	$ 17,694	$ 18,490	$ 10,494
Trade Receivables and Long-term Receivables
Accounts Notes and Loans Receivable [Line Items]
Financing receivables, consisting of sales-type leases	$ 49,973		$ 49,096

Accounts Receivable - Summary of Accounts Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts Notes and Loans Receivable [Line Items]
Gross accounts receivable	$ 84,323		$ 92,402
Unearned income	(3,640)		(3,728)
Allowance for doubtful accounts	(12,295)	$ (17,694)	(18,490)	$ (10,494)
Net accounts receivable	68,388		70,184
Current trade receivables	50,078		52,764
Current unearned interest income	(2,464)		(1,950)
Long-term receivables	21,950		21,148
Long-term unearned interest income	(1,176)		(1,778)
Trade Accounts Receivable
Accounts Notes and Loans Receivable [Line Items]
Current trade receivables	50,078		52,764
Long-term receivables	$ 21,950		$ 21,148

Accounts Receivable - Schedule of Contractual Commitments, Net of Allowance for Doubtful Accounts (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Accounts Notes and Loans Receivable [Line Items]
Total financing receivables	$ 49,973
2021	28,024
2022	15,504
2023	6,289
2024	156
Current financing receivables, net of allowance of $4,683
Accounts Notes and Loans Receivable [Line Items]
Total financing receivables	28,024
2021	28,024
Long-term financing receivables, net of allowance of $2,571
Accounts Notes and Loans Receivable [Line Items]
Total financing receivables	21,949
2022	15,504
2023	6,289
2024	$ 156

Accounts Receivable - Schedule of Contractual Commitments, Net of Allowance for Doubtful Accounts (Parenthetical) (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Receivables [Abstract]
Allowance for current financing receivables	$ 4,683
Allowance for long-term financing receivables	$ 2,571

Accounts Receivable - Summary of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Receivables [Abstract]
Balance at beginning of period	$ 17,694	$ 18,490	$ 18,490	$ 10,494	$ 10,494
Write-offs	(2,161)	(1,902)			(6,536)
Provision	(3,238)	1,106	(2,132)	$ 5,416	15,212
Sale of subsidiaries					(680)
Balance at end of period	$ 12,295	$ 17,694	$ 12,295		$ 18,490

Select Balance Sheet and Statement of Operations Information - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 1,786	$ 838
Work-in-progress	1,494	1,232
Finished goods	16,487	15,689
Total inventory	$ 19,767	$ 17,759

Select Balance Sheet and Statement of Operations Information - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Select Balance Sheet And Statement Of Operations Information [Abstract]
Cost of goods sold	$ 5,339	$ 3,603	$ 11,359	$ 7,203
Provision for inventory obsolescence	2,014		2,014		$ 1,208
Depreciation expense	$ 280	$ 400	$ 728	$ 777

Select Balance Sheet and Statement of Operations Information - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Property Plant And Equipment [Line Items]
Lab equipment tooling and molds	$ 8,104	$ 8,053
Office furniture and equipment	1,739	1,760
Leasehold improvements	1,793	1,838
Computers and software	1,863	1,815
Vehicles	20	12
Total property and equipment	13,519	13,478
Less: Accumulated depreciation	(10,582)	(9,939)
Total property and equipment, net	$ 2,937	$ 3,539
Lab Equipment Tooling and Molds \| Minimum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P4Y
Lab Equipment Tooling and Molds \| Maximum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P10Y
Office Furniture and Equipment \| Minimum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P6Y
Office Furniture and Equipment \| Maximum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P10Y
Leasehold Improvements \| Maximum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P10Y
Computers and Software
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P3Y
Vehicles \| Minimum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P5Y
Vehicles \| Maximum
Property Plant And Equipment [Line Items]
Property and equipment, Useful lives	P7Y

Select Balance Sheet and Statement of Operations Information - Schedule of Other Current Assets (Details) - USD ($)
$ in Thousands

Jun. 30, 2021

Dec. 31, 2020

Other Assets [Abstract]

Government remittances

^[1]

$ 1,436

$ 1,009

Consideration receivable from sales of subsidiaries

2,199

2,580

Deferred financing costs

223

1,063

Sundry assets and miscellaneous

777

1,022

Total other current assets

$ 4,635

$ 5,674

[1]	Government remittances are receivables from the local tax authorities for refunds of sales taxes and income taxes.

Select Balance Sheet and Statement of Operations Information - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Payroll and related expense	$ 1,442	$ 1,312
Accrued expenses	6,387	8,582
Commission accrual	2,952	2,827
Sales and consumption taxes	6,315	7,532
Total accrued expenses and other current liabilities	$ 17,096	$ 20,253

Select Balance Sheet and Statement of Operations Information - Schedule of Change in Warranty Accrual (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Product Warranty Accrual Balance Sheet Classification [Abstract]
Warranty accrual, Balance as of the beginning of the period	$ 1,639	$ 1,977
Warranties issued during the period	538	761
Warranty costs incurred during the period	(396)	(1,099)
Warranty accrual, Balance at the end of the period	1,781	1,639
Current	1,314	1,106
Long-term	$ 467	$ 533

Select Balance Sheet and Statement of Operations Information - Schedule of Finance Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Interest And Debt Expense [Abstract]
Interest expense	$ 930	$ 2,220	$ 2,068	$ 4,328
Accretion on long-term debt and amortization of fees	231	151	978	297
Total finance expenses	$ 1,161	$ 2,371	$ 3,046	$ 4,625

Intangible Assets - Schedule of Intangible Assets Net of Accumulated Amortization and Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Goodwill And Intangible Assets [Line Items]
Gross Amount	$ 23,800	$ 23,800
Accumulated Amortization	(6,656)	(4,935)
Net Amount	17,144	18,865
Customer Relationships
Goodwill And Intangible Assets [Line Items]
Gross Amount	1,400	1,400
Accumulated Amortization	(288)	(242)
Net Amount	1,112	1,158
Brand Name
Goodwill And Intangible Assets [Line Items]
Gross Amount	2,500	2,500
Accumulated Amortization	(670)	(540)
Net Amount	1,830	1,960
Technology
Goodwill And Intangible Assets [Line Items]
Gross Amount	16,900	16,900
Accumulated Amortization	(4,683)	(3,286)
Net Amount	12,217	13,614
Supplier Agreement
Goodwill And Intangible Assets [Line Items]
Gross Amount	3,000	3,000
Accumulated Amortization	(1,015)	(867)
Net Amount	$ 1,985	$ 2,133

Intangible Assets - Schedule of Estimated Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Finite Lived Intangible Assets Future Amortization Expense [Abstract]
July 1, 2021 to December 31, 2021	$ 1,752
2022	3,473
2023	3,473
2024	3,473
2025	3,004
Thereafter	1,969
Net Amount	$ 17,144	$ 18,865

Commitments and Contingencies - Summary of Future Minimum Lease Payments and Purchase and Service Commitments with Manufacturers and Service Providers (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Commitments And Contingencies Disclosure [Abstract]
July 1, 2021 to June 30, 2022, Office Lease	$ 699
2023, Office Lease	739
2024, Office Lease	345
2025, Office Lease	213
2026, Office Lease	213
Thereafter, Office Lease	1,039
Total, Office Lease	3,248
July 1, 2021 to June 30, 2022, Purchase and Service Commitments	13,548
Total, Purchase and Service Commitments	13,548
Contractual Obligation, Fiscal Year Maturity [Abstract]
July 1, 2021 to June 30, 2022	14,247
2023	739
2024	345
2025	213
2026	213
Thereafter	1,039
Total	$ 16,796

Commitments and Contingencies - Additional Information (Details) ¥ in Thousands, $ in Thousands			3 Months Ended		6 Months Ended		13 Months Ended
	Mar. 04, 2021 USD ($)	Mar. 04, 2021 CNY (¥)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 11, 2019 Complaint
Commitment And Contingencies [Line Items]
Rent expense			$ 524	$ 451	$ 1,095	$ 1,021
Purchase obligation			13,548		13,548
Number of complaints filed \| Complaint							4
Xuhui MSA Market Regulation
Commitment And Contingencies [Line Items]
Penalty amount	$ 150	¥ 976
Contract Manufacturers
Commitment And Contingencies [Line Items]
Purchase obligation			12,760		12,760
Open Purchase Order
Commitment And Contingencies [Line Items]
Purchase obligation			$ 3,092		$ 3,092
Open purchase cancellation period					270 days
Percentage of open purchase order					15.00%

Main Street Term Loan - Additional Information (Details) - MSLP Loan Agreement - USD ($) $ in Thousands				6 Months Ended
	Dec. 08, 2024	Dec. 08, 2023	Dec. 08, 2020	Jun. 30, 2021
Debt Instrument [Line Items]
Debt instrument face amount			$ 50,000
Debt instrument term			5 years
Debt instrument, description of variable rate basis			30-day LIBOR plus 3%.
Debt instrument basis spread on variable rate			3.00%
Debt instrument, maturity date				Dec. 08, 2025
Scenario Forecast
Debt Instrument [Line Items]
Debt instrument percentage of outstanding principal to be paid with accrued unpaid interest	15.00%	15.00%

Main Street Term Loan - Schedule Payments on Outstanding Borrowings (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Debt Instrument [Line Items]
2021	$ 1,092
2022	2,165
2023	2,131
2024	1,628
2025	28,217
Total	35,233
MSLP Loan Agreement
Debt Instrument [Line Items]
2022	1,599
2023	9,335
2024	7,938
2025	38,415
Total	$ 57,287

Madryn Long-term Debt and Convertible Notes - Additional Information (Details) - USD ($)		3 Months Ended	6 Months Ended
	Dec. 09, 2020	Jun. 30, 2021	Jun. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Common stock, par value		$ 0.0001	$ 0.0001	$ 0.0001
Repayments of long-term debt		$ 0	$ 0
Madryn Credit Agreement
Debt Instrument [Line Items]
Repayments of debt	$ 42,500,000
Credit agreement termination date			Dec. 09, 2020
Secured Subordinated Convertible Notes
Debt Instrument [Line Items]
Increase in applicate interest rate			4.00%
Debt instrument, interest rate terms			Interest is payable quarterly in arrears on the last business day of each calendar quarter of each year after the original issuance date, beginning on December 31, 2020.
Issuance date			Dec. 31, 2020
Debt instrument, maturity date			Dec. 09, 2025
Debt instrument termination description			The security interests and liens granted to the Madryn Noteholders under the Madryn Security Agreement will terminate upon the earlier of (i) an assignment of the Notes (other than to an affiliate of the Madryn Noteholders) pursuant to the terms of the Exchange Agreement and (ii) the first date on which the outstanding principal amount of the Notes is less than $10,000.
Common stock, par value		$ 0.0001	$ 0.0001
Initial conversion price		$ 3.25	$ 3.25
Interest expense		$ 540,000	$ 1,067,000
Secured Subordinated Convertible Notes \| Maximum
Debt Instrument [Line Items]
Debt instrument, principal amount		$ 10,000,000	$ 10,000,000
Secured Subordinated Convertible Notes \| Original Issuance of Notes to Third Anniversary Date
Debt Instrument [Line Items]
Accrue interest rate			8.00%
Secured Subordinated Convertible Notes \| Original Issuance and Thereafter
Debt Instrument [Line Items]
Accrue interest rate			6.00%
Secured Subordinated Convertible Notes \| Madryn Credit Agreement
Debt Instrument [Line Items]
Aggregate principal amount	$ 26,695,000

Madryn Long-term Debt and Convertible Notes - Schedule Payments on Outstanding Borrowings (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Debt Disclosure [Abstract]
2021	$ 1,092
2022	2,165
2023	2,131
2024	1,628
2025	28,217
Total	$ 35,233

Credit Facility - Additional Information (Details) - Revolving Credit Facility - City National Bank of Florida	6 Months Ended
	Jun. 30, 2021 USD ($)
Line Of Credit Facility [Line Items]
Revolving credit facility, maximum outstanding amount	$ 10,000,000
Line of credit facility cash held in deposit account period	1 year
Escrow deposit	$ 20,000,000
Line of credit facility minimum deposit required	3,000,000
Loan fee paid	$ 1,000,000
Installment One
Line Of Credit Facility [Line Items]
Line of credit facility loan fee payment date	January 25
Installment Two
Line Of Credit Facility [Line Items]
Line of credit facility loan fee payment date	February 25
Installment Three
Line Of Credit Facility [Line Items]
Line of credit facility loan fee payment date	March 25, 2021
Minimum
Line Of Credit Facility [Line Items]
Line of credit facility cash held in deposit account	$ 23,000,000
Line of credit facility cash held in deposit account after one year	$ 3,000,000

Government Assistance Programs - Additional Information (Details) $ in Thousands		6 Months Ended
	Apr. 29, 2020 USD ($)	Jun. 30, 2021 USD ($) Loan	Dec. 31, 2020 USD ($)	Apr. 20, 2020 USD ($)
Government Assistance Programs [Line Items]
Debt outstanding balance		$ 35,233
Government Assistance Programs \| Paycheck Protection Program \| Venus Concept USA Inc.
Government Assistance Programs [Line Items]
Number of small business loans \| Loan		2
Government Assistance Programs \| Subsidiaries \| Canada Emergency Wage Subsidy
Government Assistance Programs [Line Items]
Government subsidies received		$ 1,117
Government Assistance Programs \| Small Business Loans \| Paycheck Protection Program \| Venus Concept USA Inc.
Government Assistance Programs [Line Items]
Fund amount received		4,048
Government Assistance Programs \| Venus Concept PPP Loan \| Paycheck Protection Program
Government Assistance Programs [Line Items]
Debt instrument, principal amount	$ 1,665	1,086
Debt instrument, interest rate, stated percentage	1.00%
Debt instrument, term of maturity	2 years
Government Assistance Programs \| Venus USA PPP Loan \| Paycheck Protection Program
Government Assistance Programs [Line Items]
Debt instrument, principal amount		1,689		$ 2,383
Government Assistance Programs \| PPP Loans \| Paycheck Protection Program
Government Assistance Programs [Line Items]
Debt outstanding balance		$ 1,280	$ 4,110

Common Stock Reserved for Issuance - Schedule of Common Stock Reserved for Issuance (Details) - shares	Jun. 30, 2021	Dec. 31, 2020
Class Of Stock [Line Items]
Outstanding stock options	5,794,087	4,433,392
Total common stock reserved for issuance	35,965,295	34,422,828
Common Stock
Class Of Stock [Line Items]
Outstanding common stock warrants	15,928,867	16,290,067
Option
Class Of Stock [Line Items]
Shares reserved for future grants	805,594	262,622
Lincoln Park
Class Of Stock [Line Items]
Shares reserved for future grants	5,222,867	5,222,867
Madryn Noteholders
Class Of Stock [Line Items]
Shares reserved for future grants	8,213,880	8,213,880

Stockholders Equity - Additional Information (Details) - USD ($)		1 Months Ended			3 Months Ended			6 Months Ended
	Dec. 22, 2020	Feb. 28, 2021	Dec. 31, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 16, 2020	Oct. 04, 2019
Class Of Stock [Line Items]
Common stock voting rights								one vote
Net proceeds from private placement				$ 20,300,000					$ 20,300,000
Beneficial conversion feature				3,564,000		$ (3,564,000)	$ 3,564,000
Common stock, par value			$ 0.0001		$ 0.0001			$ 0.0001
Common stock, shares issued			53,551,126		54,141,822			54,141,822
Net proceeds from shares issuance									2,956,000
Exercises of 2020 December Public Offering Warrants								$ 903,000
Common stock reserved for issuance			34,422,828		35,965,295			35,965,295
Expected dividend								$ 0
Total intrinsic value of options exercised					$ 247,000	$ 46,000		$ 404,000	$ 46,000
Weighted-average grant date fair value of options granted					$ 1.96	$ 4.26		$ 2.34	$ 4.355
2010 Share Option Plan
Class Of Stock [Line Items]
Stock option, vesting period								7 years
Stock option, vesting period extension								10 years
Common stock reserved for issuance			138,275		180,208			180,208
2019 Incentive Award Plan
Class Of Stock [Line Items]
Common stock reserved for issuance			124,347		625,386			625,386			450,000
Percentage of stock outstanding								4.00%
2020 Private Placement Warrants
Class Of Stock [Line Items]
Net proceeds from private placement				$ 4,621,000
December 2020 Public Offering Warrants and Common Stock
Class Of Stock [Line Items]
Net proceeds from shares issuance			$ 20,476,000
December 2020 Public Offering Warrants
Class Of Stock [Line Items]
Warrants to purchase shares of common stock		361,200
Exercise price of warrants	$ 2.50	$ 2.50
Warrants expiry period	5 years
Warrants exercisable period								The December 2020 Public Offering Warrants have a five-year term and are exercisable immediately.
Net proceeds from shares issuance			$ 2,648,000
Exercises of 2020 December Public Offering Warrants		$ 903,000
December 2020 Public Offering Warrants \| Maximum
Class Of Stock [Line Items]
Warrants to purchase shares of common stock	5,625,000
Investor \| 2020 Private Placement Warrants
Class Of Stock [Line Items]
Exercise price of warrants				$ 3.50			$ 3.50
Warrants expiry period				5 years
Warrants exercisable period								beginning 181 days after their issue date
Investor \| 2020 Private Placement Warrants \| Maximum
Class Of Stock [Line Items]
Warrants to purchase shares of common stock				6,675,000			6,675,000
Investor \| December 2020 Public Offering Warrants and Common Stock
Class Of Stock [Line Items]
Exercise price of warrants			$ 2.50
Warrants expiry period			5 years
Warrants exercisable period								The December 2020 Public Offering Warrants have a five-year term and are exercisable immediately.
Common stock, shares issued			11,250,000
Investor \| December 2020 Public Offering Warrants and Common Stock \| Maximum
Class Of Stock [Line Items]
Warrants to purchase shares of common stock			5,625,000
Investor \| December 2020 Public Offering Warrants
Class Of Stock [Line Items]
Warrants to purchase shares of common stock		361,200
Exercise price of warrants		$ 2.50
Exercises of 2020 December Public Offering Warrants		$ 903,000
Common Stock
Class Of Stock [Line Items]
Net proceeds from private placement				$ 4,052,000
Conversion of Preferred Stock Series A, shares										6,600,000
Common Stock \| 2020 Private Placement Warrants
Class Of Stock [Line Items]
Common stock, par value				$ 0.0001			$ 0.0001
Common Stock \| December 2020 Public Offering Warrants and Common Stock
Class Of Stock [Line Items]
Common stock, par value			$ 0.0001
Net proceeds from shares issuance			$ 17,828,000
Series A Preferred Shares
Class Of Stock [Line Items]
Net proceeds from private placement				$ 8,063,000
Conversion of Preferred Stock Series A, shares										660,000
Series A Preferred Shares \| 2020 Private Placement Warrants
Class Of Stock [Line Items]
Preferred stock, par value				$ 0.0001			$ 0.0001

Stockholders Equity - Summary of Recognized Stock-based Compensation Expense for Employees and Non-employees (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation			$ 1,066	$ 1,056
Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$ 558	$ 539	1,066	1,056
Cost of Sales \| Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	8	6	15	12
Selling and Marketing \| Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	224	222	441	414
General and Administrative \| Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	297	284	561	583
Research and Development \| Employees and Non-employees
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation	$ 29	$ 27	$ 49	$ 47

Stockholders Equity - Assumptions used in Fair Value of Option Estimated at Date of Grant using Black-Scholes Option Pricing Formula (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years	6 years 3 months 25 days	6 years
Risk-free interest rate		0.65%
Expected volatility	44.00%	43.26%	44.75%	42.61%
Expected dividend rate	0.00%	0.00%	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)				5 years
Risk-free interest rate	1.01%		1.01%	0.57%
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)				6 years 7 months 20 days
Risk-free interest rate	1.08%		1.09%	1.50%

Stockholders Equity - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward
Number of Shares, Outstanding, Beginning Balance			4,433,392
Number of Shares, Options granted			1,984,500
Number of Shares, Options exercised			(229,496)
Number of Shares, Options forfeited/cancelled			(394,309)
Number of Shares, Outstanding, Ending Balance	5,794,087		5,794,087		4,433,392
Number of Shares, Exercisable	2,593,882		2,593,882
Number of Shares, Expected to vest	3,200,205		3,200,205
Weighted-Average Exercise Price Per Share, Outstanding, Beginning Balance			$ 4.59
Weighted-Average Exercise Price Per Share, Options granted			2.34
Weighted-Average Exercise Price Per Share, Options exercised			2.35
Weighted-Average Exercise Price Per Share, Options forfeited/cancelled			4.68
Weighted-Average Exercise Price Per Share, Outstanding, Ending Balance	$ 3.94		3.94		$ 4.59
Weighted-Average Exercise Price Per Share, Exercisable	4.70		4.70
Weighted-Average Exercise Price Per Share, Expected to vest	$ 3.34		$ 3.34
Weighted-Average Remaining Contractual Term, Outstanding			7 years 3 months 21 days		6 years 2 months 12 days
Weighted-Average Remaining Contractual Term, Exercisable			5 years
Weighted-Average Remaining Contractual Term, Expected to vest			9 years 2 months 4 days
Aggregate Intrinsic Value, Outstanding	$ 2,279		$ 2,279		$ 247
Aggregate Intrinsic Value, Options granted			1,520
Aggregate Intrinsic Value, Options exercised	247	$ 46	$ 404	$ 46
Aggregate Intrinsic Value, Options forfeited/cancelled			$ 25
Aggregate Intrinsic Value, Exercisable	823		$ 823
Aggregate Intrinsic Value, Expected to vest – after June 30, 2021	$ 1,456		$ 1,456

Stockholders Equity - Summary of Information about Stock Options Outstanding and Exercisable (Details)	6 Months Ended
	Jun. 30, 2021 $ / shares shares
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Options Outstanding, Number \| shares	5,794,087
Options Outstanding, Weighted average remaining contractual term (years)	7 years 3 months 21 days
Options Outstanding, Weighted average Exercise Price	$ 3.94
Options Exercisable \| shares	2,593,882
Options Exercisable, Weighted average remaining contractual term (years)	5 years
Options Exercisable, Weighted average Exercise Price	$ 4.70
$1.35 - $3.64
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price Range (Lower limit)	1.35
Exercise Price Range (Upper limit)	$ 3.64
Options Outstanding, Number \| shares	4,391,390
Options Outstanding, Weighted average remaining contractual term (years)	7 years 7 months 6 days
Options Outstanding, Weighted average Exercise Price	$ 2.80
Options Exercisable \| shares	1,587,140
Options Exercisable, Weighted average remaining contractual term (years)	4 years 6 months 10 days
Options Exercisable, Weighted average Exercise Price	$ 2.92
$4.26 - $7.95
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price Range (Lower limit)	4.26
Exercise Price Range (Upper limit)	$ 7.95
Options Outstanding, Number \| shares	1,347,661
Options Outstanding, Weighted average remaining contractual term (years)	6 years 5 months 8 days
Options Outstanding, Weighted average Exercise Price	$ 6.81
Options Exercisable \| shares	962,519
Options Exercisable, Weighted average remaining contractual term (years)	5 years 9 months
Options Exercisable, Weighted average Exercise Price	$ 6.62
$12.45 - $26.10
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price Range (Lower limit)	12.45
Exercise Price Range (Upper limit)	$ 26.10
Options Outstanding, Number \| shares	33,659
Options Outstanding, Weighted average remaining contractual term (years)	6 years 9 months
Options Outstanding, Weighted average Exercise Price	$ 18.48
Options Exercisable \| shares	23,033
Options Exercisable, Weighted average remaining contractual term (years)	6 years 6 months 25 days
Options Exercisable, Weighted average Exercise Price	$ 18.82
$27.00 - $33.00
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price Range (Lower limit)	27
Exercise Price Range (Upper limit)	$ 33.00
Options Outstanding, Number \| shares	12,998
Options Outstanding, Weighted average remaining contractual term (years)	3 years 3 months 14 days
Options Outstanding, Weighted average Exercise Price	$ 27.99
Options Exercisable \| shares	12,968
Options Exercisable, Weighted average remaining contractual term (years)	3 years 3 months 10 days
Options Exercisable, Weighted average Exercise Price	$ 27.98
$36.00 - $94.65
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]
Exercise Price Range (Lower limit)	36.00
Exercise Price Range (Upper limit)	$ 94.65
Options Outstanding, Number \| shares	8,379
Options Outstanding, Weighted average remaining contractual term (years)	6 years 2 months 8 days
Options Outstanding, Weighted average Exercise Price	$ 45.42
Options Exercisable \| shares	8,222
Options Exercisable, Weighted average remaining contractual term (years)	6 years 2 months 4 days
Options Exercisable, Weighted average Exercise Price	$ 45.17

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Tax (benefit) expense	$ (7)	$ (633)	$ (7)	$ (44)

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

Income Taxes - Schedule of Reconciliation of Income Tax Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]
Income (loss) before income taxes	$ 235	$ (10,398)	$ (9,200)	$ (60,512)
Theoretical tax expense (benefit) at the statutory rate (21.0% in 2021, 24.1% in 2020)	49	(2,507)	(1,932)	(14,584)
Differences in jurisdictional tax rates	(49)	(48)	(403)	(220)
Losses recognition		101
Valuation allowance	315	1,936	2,299	7,298
Non-deductible expenses	(395)	(115)	(61)	7,462
Other	73		90
Total income tax benefit	(7)	(633)	(7)	(44)
Net income (loss)	$ 242	$ (9,765)	$ (9,193)	$ (60,468)

Income Taxes - Schedule of Reconciliation of Income Tax Expense (Parenthetical) (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]
Theoretical tax benefit, statutory rate	21.00%	24.10%

Segment and Geographic Information - Additional Information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($) Segment	Dec. 31, 2020 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments \| Segment	1
Number of reportable segments \| Segment	1
Lease Revenue
Segment Reporting Information [Line Items]
System sales with typical lease terms	36 months
System Revenue
Segment Reporting Information [Line Items]
Systems sales with payment terms	12 months
United States
Segment Reporting Information [Line Items]
Long-lived assets \| $	$ 17,906	$ 19,828
Foreign
Segment Reporting Information [Line Items]
Long-lived assets \| $	$ 2,175	$ 2,576

Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue	$ 25,828	$ 16,996	$ 48,425	$ 31,504
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue	13,186	8,915	24,063	14,555
Foreign
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenue	$ 12,642	$ 8,081	$ 24,362	$ 16,949

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

Segment and Geographic Information - Schedule of Revenue by Type (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Entity Wide Information Revenue From External Customer [Line Items]
Total revenue	$ 25,828	$ 16,996	$ 48,425	$ 31,504
Lease Revenue
Entity Wide Information Revenue From External Customer [Line Items]
Total revenue	12,787	7,465	21,324	14,278
System Revenue
Entity Wide Information Revenue From External Customer [Line Items]
Total revenue	8,694	6,757	18,504	10,255
Product Revenue
Entity Wide Information Revenue From External Customer [Line Items]
Total revenue	3,314	1,787	6,369	4,504
Service Revenue
Entity Wide Information Revenue From External Customer [Line Items]
Total revenue	$ 1,033	$ 987	$ 2,228	$ 2,467

- Definition

+ References

+ Details

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Med Group Consult Ltd \| Venus Concept Singapore Pte. Ltd
Related Party Transaction [Line Items]
Percentage of ownership interest in subsidiaries sold				55.00%
Senior Officer \| TBC
Related Party Transaction [Line Items]
Percentage of ownership by senior officer in TBC	30.00%	30.00%
Senior Officer \| Venus Concept Singapore Pte. Ltd
Related Party Transaction [Line Items]
Percentage of ownership by senior officer	45.00%	45.00%
TBC
Related Party Transaction [Line Items]
Products purchased	$ 113	$ 128	$ 49
Venus Concept Singapore Pte. Ltd
Related Party Transaction [Line Items]
Products purchased	$ 49	$ 114